WO2012033151A1 - 炎症を抑制する組成物 - Google Patents
炎症を抑制する組成物 Download PDFInfo
- Publication number
- WO2012033151A1 WO2012033151A1 PCT/JP2011/070436 JP2011070436W WO2012033151A1 WO 2012033151 A1 WO2012033151 A1 WO 2012033151A1 JP 2011070436 W JP2011070436 W JP 2011070436W WO 2012033151 A1 WO2012033151 A1 WO 2012033151A1
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- ahr
- probiotic
- composition
- strain
- probiotics
- Prior art date
Links
- 239000000203 mixture Substances 0.000 title claims abstract description 53
- 230000003405 preventing effect Effects 0.000 title description 7
- 206010061218 Inflammation Diseases 0.000 title description 6
- 230000004054 inflammatory process Effects 0.000 title description 6
- 239000006041 probiotic Substances 0.000 claims abstract description 88
- 235000018291 probiotics Nutrition 0.000 claims abstract description 88
- 239000002260 anti-inflammatory agent Substances 0.000 claims abstract description 27
- 229940121363 anti-inflammatory agent Drugs 0.000 claims abstract description 27
- JVTAAEKCZFNVCJ-UHFFFAOYSA-N lactic acid Chemical compound CC(O)C(O)=O JVTAAEKCZFNVCJ-UHFFFAOYSA-N 0.000 claims description 60
- 241000894006 Bacteria Species 0.000 claims description 50
- 230000004913 activation Effects 0.000 claims description 50
- 230000000529 probiotic effect Effects 0.000 claims description 44
- 230000014509 gene expression Effects 0.000 claims description 41
- 239000004310 lactic acid Substances 0.000 claims description 30
- 235000014655 lactic acid Nutrition 0.000 claims description 30
- 235000013305 food Nutrition 0.000 claims description 23
- XBDQKXXYIPTUBI-UHFFFAOYSA-N dimethylselenoniopropionate Natural products CCC(O)=O XBDQKXXYIPTUBI-UHFFFAOYSA-N 0.000 claims description 16
- 108700008625 Reporter Genes Proteins 0.000 claims description 14
- 239000012228 culture supernatant Substances 0.000 claims description 14
- 241000186000 Bifidobacterium Species 0.000 claims description 10
- 241000186673 Lactobacillus delbrueckii Species 0.000 claims description 10
- 235000013361 beverage Nutrition 0.000 claims description 10
- 239000008194 pharmaceutical composition Substances 0.000 claims description 9
- 235000019260 propionic acid Nutrition 0.000 claims description 8
- IUVKMZGDUIUOCP-BTNSXGMBSA-N quinbolone Chemical compound O([C@H]1CC[C@H]2[C@H]3[C@@H]([C@]4(C=CC(=O)C=C4CC3)C)CC[C@@]21C)C1=CCCC1 IUVKMZGDUIUOCP-BTNSXGMBSA-N 0.000 claims description 8
- 230000004936 stimulating effect Effects 0.000 claims description 6
- 108091027981 Response element Proteins 0.000 claims description 4
- 241000238876 Acari Species 0.000 claims 1
- 238000000034 method Methods 0.000 abstract description 19
- 210000001035 gastrointestinal tract Anatomy 0.000 abstract description 14
- 238000012216 screening Methods 0.000 abstract description 14
- 230000003213 activating effect Effects 0.000 abstract description 11
- 230000006749 inflammatory damage Effects 0.000 abstract 1
- 210000004027 cell Anatomy 0.000 description 71
- BLFLLBZGZJTVJG-UHFFFAOYSA-N benzocaine Chemical compound CCOC(=O)C1=CC=C(N)C=C1 BLFLLBZGZJTVJG-UHFFFAOYSA-N 0.000 description 35
- 235000013618 yogurt Nutrition 0.000 description 27
- 230000000694 effects Effects 0.000 description 25
- 239000000047 product Substances 0.000 description 22
- 238000004519 manufacturing process Methods 0.000 description 17
- 206010009887 colitis Diseases 0.000 description 16
- XEYBRNLFEZDVAW-ARSRFYASSA-N dinoprostone Chemical compound CCCCC[C@H](O)\C=C\[C@H]1[C@H](O)CC(=O)[C@@H]1C\C=C/CCCC(O)=O XEYBRNLFEZDVAW-ARSRFYASSA-N 0.000 description 16
- 238000003556 assay Methods 0.000 description 14
- 229960002986 dinoprostone Drugs 0.000 description 14
- XEYBRNLFEZDVAW-UHFFFAOYSA-N prostaglandin E2 Natural products CCCCCC(O)C=CC1C(O)CC(=O)C1CC=CCCCC(O)=O XEYBRNLFEZDVAW-UHFFFAOYSA-N 0.000 description 14
- 108090000623 proteins and genes Proteins 0.000 description 12
- 208000027866 inflammatory disease Diseases 0.000 description 11
- 230000000968 intestinal effect Effects 0.000 description 11
- 230000000638 stimulation Effects 0.000 description 11
- 239000000126 substance Substances 0.000 description 11
- 239000000725 suspension Substances 0.000 description 11
- 102100038280 Prostaglandin G/H synthase 2 Human genes 0.000 description 9
- 230000003110 anti-inflammatory effect Effects 0.000 description 9
- 230000001580 bacterial effect Effects 0.000 description 9
- 230000037396 body weight Effects 0.000 description 9
- 210000002429 large intestine Anatomy 0.000 description 9
- 239000007858 starting material Substances 0.000 description 9
- HGUFODBRKLSHSI-UHFFFAOYSA-N 2,3,7,8-tetrachloro-dibenzo-p-dioxin Chemical compound O1C2=CC(Cl)=C(Cl)C=C2OC2=C1C=C(Cl)C(Cl)=C2 HGUFODBRKLSHSI-UHFFFAOYSA-N 0.000 description 8
- 108050003267 Prostaglandin G/H synthase 2 Proteins 0.000 description 8
- 235000015140 cultured milk Nutrition 0.000 description 8
- 235000013365 dairy product Nutrition 0.000 description 8
- 238000001727 in vivo Methods 0.000 description 8
- 244000005700 microbiome Species 0.000 description 8
- 235000013336 milk Nutrition 0.000 description 8
- 239000008267 milk Substances 0.000 description 8
- 210000004080 milk Anatomy 0.000 description 8
- 102000008142 Cytochrome P-450 CYP1A1 Human genes 0.000 description 7
- 108010074918 Cytochrome P-450 CYP1A1 Proteins 0.000 description 7
- 244000199885 Lactobacillus bulgaricus Species 0.000 description 7
- 235000013960 Lactobacillus bulgaricus Nutrition 0.000 description 7
- 230000002757 inflammatory effect Effects 0.000 description 7
- 229940004208 lactobacillus bulgaricus Drugs 0.000 description 7
- 239000003446 ligand Substances 0.000 description 7
- 239000013612 plasmid Substances 0.000 description 7
- 235000018102 proteins Nutrition 0.000 description 7
- 102000004169 proteins and genes Human genes 0.000 description 7
- 238000012360 testing method Methods 0.000 description 7
- 238000011282 treatment Methods 0.000 description 7
- TWRXJAOTZQYOKJ-UHFFFAOYSA-L Magnesium chloride Chemical compound [Mg+2].[Cl-].[Cl-] TWRXJAOTZQYOKJ-UHFFFAOYSA-L 0.000 description 6
- 241000699670 Mus sp. Species 0.000 description 6
- 238000011529 RT qPCR Methods 0.000 description 6
- 229920002472 Starch Polymers 0.000 description 6
- 150000001720 carbohydrates Chemical class 0.000 description 6
- 230000002354 daily effect Effects 0.000 description 6
- 239000000796 flavoring agent Substances 0.000 description 6
- 230000006698 induction Effects 0.000 description 6
- 239000013642 negative control Substances 0.000 description 6
- 239000003921 oil Substances 0.000 description 6
- 235000019198 oils Nutrition 0.000 description 6
- BWHMMNNQKKPAPP-UHFFFAOYSA-L potassium carbonate Chemical compound [K+].[K+].[O-]C([O-])=O BWHMMNNQKKPAPP-UHFFFAOYSA-L 0.000 description 6
- 239000000843 powder Substances 0.000 description 6
- 238000002360 preparation method Methods 0.000 description 6
- 239000008107 starch Substances 0.000 description 6
- 235000019698 starch Nutrition 0.000 description 6
- 230000004083 survival effect Effects 0.000 description 6
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 6
- 102000003896 Myeloperoxidases Human genes 0.000 description 5
- 108090000235 Myeloperoxidases Proteins 0.000 description 5
- 102000007544 Whey Proteins Human genes 0.000 description 5
- 108010046377 Whey Proteins Proteins 0.000 description 5
- 239000003242 anti bacterial agent Substances 0.000 description 5
- 229940088710 antibiotic agent Drugs 0.000 description 5
- -1 elixir Substances 0.000 description 5
- 238000000338 in vitro Methods 0.000 description 5
- 150000002632 lipids Chemical class 0.000 description 5
- 239000007788 liquid Substances 0.000 description 5
- 108020003175 receptors Proteins 0.000 description 5
- 239000000523 sample Substances 0.000 description 5
- 229930003231 vitamin Natural products 0.000 description 5
- 235000013343 vitamin Nutrition 0.000 description 5
- 239000011782 vitamin Substances 0.000 description 5
- 229940088594 vitamin Drugs 0.000 description 5
- MZOFCQQQCNRIBI-VMXHOPILSA-N (3s)-4-[[(2s)-1-[[(2s)-1-[[(1s)-1-carboxy-2-hydroxyethyl]amino]-4-methyl-1-oxopentan-2-yl]amino]-5-(diaminomethylideneamino)-1-oxopentan-2-yl]amino]-3-[[2-[[(2s)-2,6-diaminohexanoyl]amino]acetyl]amino]-4-oxobutanoic acid Chemical compound OC[C@@H](C(O)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CCCN=C(N)N)NC(=O)[C@H](CC(O)=O)NC(=O)CNC(=O)[C@@H](N)CCCCN MZOFCQQQCNRIBI-VMXHOPILSA-N 0.000 description 4
- 102000011632 Caseins Human genes 0.000 description 4
- 108010076119 Caseins Proteins 0.000 description 4
- 108060008682 Tumor Necrosis Factor Proteins 0.000 description 4
- 102000000852 Tumor Necrosis Factor-alpha Human genes 0.000 description 4
- 230000009471 action Effects 0.000 description 4
- 230000009286 beneficial effect Effects 0.000 description 4
- 235000014633 carbohydrates Nutrition 0.000 description 4
- 239000003795 chemical substances by application Substances 0.000 description 4
- 210000001072 colon Anatomy 0.000 description 4
- 239000002158 endotoxin Substances 0.000 description 4
- 235000019634 flavors Nutrition 0.000 description 4
- 102000006602 glyceraldehyde-3-phosphate dehydrogenase Human genes 0.000 description 4
- 108020004445 glyceraldehyde-3-phosphate dehydrogenase Proteins 0.000 description 4
- 210000000936 intestine Anatomy 0.000 description 4
- 229920006008 lipopolysaccharide Polymers 0.000 description 4
- 239000002609 medium Substances 0.000 description 4
- 229910052751 metal Inorganic materials 0.000 description 4
- 239000002184 metal Substances 0.000 description 4
- 150000002739 metals Chemical class 0.000 description 4
- 230000000704 physical effect Effects 0.000 description 4
- 230000028327 secretion Effects 0.000 description 4
- 108091003079 Bovine Serum Albumin Proteins 0.000 description 3
- 208000004232 Enteritis Diseases 0.000 description 3
- 206010061172 Gastrointestinal injury Diseases 0.000 description 3
- 208000022559 Inflammatory bowel disease Diseases 0.000 description 3
- 241000699666 Mus <mouse, genus> Species 0.000 description 3
- PVNIIMVLHYAWGP-UHFFFAOYSA-N Niacin Chemical compound OC(=O)C1=CC=CN=C1 PVNIIMVLHYAWGP-UHFFFAOYSA-N 0.000 description 3
- HEMHJVSKTPXQMS-UHFFFAOYSA-M Sodium hydroxide Chemical compound [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 description 3
- 239000004480 active ingredient Substances 0.000 description 3
- 238000004166 bioassay Methods 0.000 description 3
- 239000002775 capsule Substances 0.000 description 3
- 235000013351 cheese Nutrition 0.000 description 3
- 201000010099 disease Diseases 0.000 description 3
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 3
- 239000012091 fetal bovine serum Substances 0.000 description 3
- 239000008187 granular material Substances 0.000 description 3
- 239000007924 injection Substances 0.000 description 3
- 238000002347 injection Methods 0.000 description 3
- 229910001629 magnesium chloride Inorganic materials 0.000 description 3
- 229960002337 magnesium chloride Drugs 0.000 description 3
- 229940099596 manganese sulfate Drugs 0.000 description 3
- 239000011702 manganese sulphate Substances 0.000 description 3
- 235000007079 manganese sulphate Nutrition 0.000 description 3
- SQQMAOCOWKFBNP-UHFFFAOYSA-L manganese(II) sulfate Chemical compound [Mn+2].[O-]S([O-])(=O)=O SQQMAOCOWKFBNP-UHFFFAOYSA-L 0.000 description 3
- 238000002156 mixing Methods 0.000 description 3
- 229910000027 potassium carbonate Inorganic materials 0.000 description 3
- 229940093956 potassium carbonate Drugs 0.000 description 3
- 238000011160 research Methods 0.000 description 3
- 239000007787 solid Substances 0.000 description 3
- 239000000243 solution Substances 0.000 description 3
- 239000003826 tablet Substances 0.000 description 3
- 235000021119 whey protein Nutrition 0.000 description 3
- NWONKYPBYAMBJT-UHFFFAOYSA-L zinc sulfate Chemical compound [Zn+2].[O-]S([O-])(=O)=O NWONKYPBYAMBJT-UHFFFAOYSA-L 0.000 description 3
- 229960001763 zinc sulfate Drugs 0.000 description 3
- 229910000368 zinc sulfate Inorganic materials 0.000 description 3
- YBJHBAHKTGYVGT-ZKWXMUAHSA-N (+)-Biotin Chemical compound N1C(=O)N[C@@H]2[C@H](CCCCC(=O)O)SC[C@@H]21 YBJHBAHKTGYVGT-ZKWXMUAHSA-N 0.000 description 2
- GHOKWGTUZJEAQD-ZETCQYMHSA-N (D)-(+)-Pantothenic acid Chemical compound OCC(C)(C)[C@@H](O)C(=O)NCCC(O)=O GHOKWGTUZJEAQD-ZETCQYMHSA-N 0.000 description 2
- GVJHHUAWPYXKBD-UHFFFAOYSA-N (±)-α-Tocopherol Chemical group OC1=C(C)C(C)=C2OC(CCCC(C)CCCC(C)CCCC(C)C)(C)CCC2=C1C GVJHHUAWPYXKBD-UHFFFAOYSA-N 0.000 description 2
- VFMMPHCGEFXGIP-UHFFFAOYSA-N 7,8-Benzoflavone Chemical compound O1C2=C3C=CC=CC3=CC=C2C(=O)C=C1C1=CC=CC=C1 VFMMPHCGEFXGIP-UHFFFAOYSA-N 0.000 description 2
- GUBGYTABKSRVRQ-XLOQQCSPSA-N Alpha-Lactose Chemical compound O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@H]1O[C@@H]1[C@@H](CO)O[C@H](O)[C@H](O)[C@H]1O GUBGYTABKSRVRQ-XLOQQCSPSA-N 0.000 description 2
- 102000008056 Aryl Hydrocarbon Receptor Nuclear Translocator Human genes 0.000 description 2
- 108010049386 Aryl Hydrocarbon Receptor Nuclear Translocator Proteins 0.000 description 2
- CIWBSHSKHKDKBQ-JLAZNSOCSA-N Ascorbic acid Chemical group OC[C@H](O)[C@H]1OC(=O)C(O)=C1O CIWBSHSKHKDKBQ-JLAZNSOCSA-N 0.000 description 2
- IJGRMHOSHXDMSA-UHFFFAOYSA-N Atomic nitrogen Chemical compound N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 description 2
- 101150071146 COX2 gene Proteins 0.000 description 2
- OYPRJOBELJOOCE-UHFFFAOYSA-N Calcium Chemical compound [Ca] OYPRJOBELJOOCE-UHFFFAOYSA-N 0.000 description 2
- 229920002134 Carboxymethyl cellulose Polymers 0.000 description 2
- 108020004414 DNA Proteins 0.000 description 2
- RTZKZFJDLAIYFH-UHFFFAOYSA-N Diethyl ether Chemical compound CCOCC RTZKZFJDLAIYFH-UHFFFAOYSA-N 0.000 description 2
- 241000233866 Fungi Species 0.000 description 2
- 101150112014 Gapdh gene Proteins 0.000 description 2
- 208000018522 Gastrointestinal disease Diseases 0.000 description 2
- 108010043121 Green Fluorescent Proteins Proteins 0.000 description 2
- 102000004144 Green Fluorescent Proteins Human genes 0.000 description 2
- 101000605127 Homo sapiens Prostaglandin G/H synthase 2 Proteins 0.000 description 2
- XEEYBQQBJWHFJM-UHFFFAOYSA-N Iron Chemical compound [Fe] XEEYBQQBJWHFJM-UHFFFAOYSA-N 0.000 description 2
- 241000186660 Lactobacillus Species 0.000 description 2
- GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 description 2
- 108010006519 Molecular Chaperones Proteins 0.000 description 2
- 102000005431 Molecular Chaperones Human genes 0.000 description 2
- 241000194020 Streptococcus thermophilus Species 0.000 description 2
- 239000005862 Whey Substances 0.000 description 2
- 239000000654 additive Substances 0.000 description 2
- YZXBAPSDXZZRGB-DOFZRALJSA-N arachidonic acid Chemical compound CCCCC\C=C/C\C=C/C\C=C/C\C=C/CCCC(O)=O YZXBAPSDXZZRGB-DOFZRALJSA-N 0.000 description 2
- 239000011575 calcium Substances 0.000 description 2
- 229910052791 calcium Inorganic materials 0.000 description 2
- 235000010948 carboxy methyl cellulose Nutrition 0.000 description 2
- 239000000969 carrier Substances 0.000 description 2
- 239000000306 component Substances 0.000 description 2
- 150000001875 compounds Chemical class 0.000 description 2
- 101150055214 cyp1a1 gene Proteins 0.000 description 2
- 238000001514 detection method Methods 0.000 description 2
- 150000002013 dioxins Chemical class 0.000 description 2
- 239000002552 dosage form Substances 0.000 description 2
- 229940079593 drug Drugs 0.000 description 2
- 239000003814 drug Substances 0.000 description 2
- 239000003937 drug carrier Substances 0.000 description 2
- 239000000839 emulsion Substances 0.000 description 2
- 238000002474 experimental method Methods 0.000 description 2
- 239000000284 extract Substances 0.000 description 2
- 235000013861 fat-free Nutrition 0.000 description 2
- 238000000855 fermentation Methods 0.000 description 2
- 230000004151 fermentation Effects 0.000 description 2
- 235000021001 fermented dairy product Nutrition 0.000 description 2
- 239000012467 final product Substances 0.000 description 2
- 235000013355 food flavoring agent Nutrition 0.000 description 2
- 230000037406 food intake Effects 0.000 description 2
- 239000005090 green fluorescent protein Substances 0.000 description 2
- 238000010438 heat treatment Methods 0.000 description 2
- 229910052500 inorganic mineral Inorganic materials 0.000 description 2
- 239000008101 lactose Substances 0.000 description 2
- 235000021056 liquid food Nutrition 0.000 description 2
- 238000011866 long-term treatment Methods 0.000 description 2
- 239000012533 medium component Substances 0.000 description 2
- 230000000813 microbial effect Effects 0.000 description 2
- 235000021243 milk fat Nutrition 0.000 description 2
- 239000011707 mineral Substances 0.000 description 2
- 235000010755 mineral Nutrition 0.000 description 2
- 229960003512 nicotinic acid Drugs 0.000 description 2
- 235000001968 nicotinic acid Nutrition 0.000 description 2
- 239000011664 nicotinic acid Substances 0.000 description 2
- 235000016709 nutrition Nutrition 0.000 description 2
- 238000007911 parenteral administration Methods 0.000 description 2
- 239000000546 pharmaceutical excipient Substances 0.000 description 2
- KJFMBFZCATUALV-UHFFFAOYSA-N phenolphthalein Chemical compound C1=CC(O)=CC=C1C1(C=2C=CC(O)=CC=2)C2=CC=CC=C2C(=O)O1 KJFMBFZCATUALV-UHFFFAOYSA-N 0.000 description 2
- 239000006187 pill Substances 0.000 description 2
- 150000003071 polychlorinated biphenyls Chemical class 0.000 description 2
- 239000013641 positive control Substances 0.000 description 2
- 230000001737 promoting effect Effects 0.000 description 2
- 238000003753 real-time PCR Methods 0.000 description 2
- 230000003248 secreting effect Effects 0.000 description 2
- 230000019491 signal transduction Effects 0.000 description 2
- 235000020183 skimmed milk Nutrition 0.000 description 2
- 208000024891 symptom Diseases 0.000 description 2
- 239000006188 syrup Substances 0.000 description 2
- 235000020357 syrup Nutrition 0.000 description 2
- 238000013518 transcription Methods 0.000 description 2
- 230000035897 transcription Effects 0.000 description 2
- 230000009466 transformation Effects 0.000 description 2
- 238000012795 verification Methods 0.000 description 2
- FPIPGXGPPPQFEQ-UHFFFAOYSA-N 13-cis retinol Natural products OCC=C(C)C=CC=C(C)C=CC1=C(C)CCCC1(C)C FPIPGXGPPPQFEQ-UHFFFAOYSA-N 0.000 description 1
- 102000002260 Alkaline Phosphatase Human genes 0.000 description 1
- 108020004774 Alkaline Phosphatase Proteins 0.000 description 1
- 241000606125 Bacteroides Species 0.000 description 1
- GHOKWGTUZJEAQD-UHFFFAOYSA-N Chick antidermatitis factor Natural products OCC(C)(C)C(O)C(=O)NCCC(O)=O GHOKWGTUZJEAQD-UHFFFAOYSA-N 0.000 description 1
- 206010009900 Colitis ulcerative Diseases 0.000 description 1
- 108091035707 Consensus sequence Proteins 0.000 description 1
- RYGMFSIKBFXOCR-UHFFFAOYSA-N Copper Chemical compound [Cu] RYGMFSIKBFXOCR-UHFFFAOYSA-N 0.000 description 1
- 229920002261 Corn starch Polymers 0.000 description 1
- 102000002004 Cytochrome P-450 Enzyme System Human genes 0.000 description 1
- 108010015742 Cytochrome P-450 Enzyme System Proteins 0.000 description 1
- 102000004127 Cytokines Human genes 0.000 description 1
- 108090000695 Cytokines Proteins 0.000 description 1
- FBPFZTCFMRRESA-KVTDHHQDSA-N D-Mannitol Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-KVTDHHQDSA-N 0.000 description 1
- ZZZCUOFIHGPKAK-UHFFFAOYSA-N D-erythro-ascorbic acid Natural products OCC1OC(=O)C(O)=C1O ZZZCUOFIHGPKAK-UHFFFAOYSA-N 0.000 description 1
- 229920001353 Dextrin Polymers 0.000 description 1
- 239000004375 Dextrin Substances 0.000 description 1
- 108010082495 Dietary Plant Proteins Proteins 0.000 description 1
- 239000006144 Dulbecco’s modified Eagle's medium Substances 0.000 description 1
- 238000002965 ELISA Methods 0.000 description 1
- 238000008157 ELISA kit Methods 0.000 description 1
- 102000002322 Egg Proteins Human genes 0.000 description 1
- 108010000912 Egg Proteins Proteins 0.000 description 1
- 241000588724 Escherichia coli Species 0.000 description 1
- 241000186394 Eubacterium Species 0.000 description 1
- 241000192125 Firmicutes Species 0.000 description 1
- 108010010803 Gelatin Proteins 0.000 description 1
- 108700028146 Genetic Enhancer Elements Proteins 0.000 description 1
- 238000003794 Gram staining Methods 0.000 description 1
- 102100034051 Heat shock protein HSP 90-alpha Human genes 0.000 description 1
- SQUHHTBVTRBESD-UHFFFAOYSA-N Hexa-Ac-myo-Inositol Natural products CC(=O)OC1C(OC(C)=O)C(OC(C)=O)C(OC(C)=O)C(OC(C)=O)C1OC(C)=O SQUHHTBVTRBESD-UHFFFAOYSA-N 0.000 description 1
- 101000941690 Homo sapiens Cytochrome P450 1A1 Proteins 0.000 description 1
- 101000725401 Homo sapiens Cytochrome c oxidase subunit 2 Proteins 0.000 description 1
- 101001016865 Homo sapiens Heat shock protein HSP 90-alpha Proteins 0.000 description 1
- 229920002153 Hydroxypropyl cellulose Polymers 0.000 description 1
- DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical compound C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 description 1
- 102000004407 Lactalbumin Human genes 0.000 description 1
- 108090000942 Lactalbumin Proteins 0.000 description 1
- 102000010445 Lactoferrin Human genes 0.000 description 1
- 108010063045 Lactoferrin Proteins 0.000 description 1
- 102000008192 Lactoglobulins Human genes 0.000 description 1
- 108010060630 Lactoglobulins Proteins 0.000 description 1
- 108060001084 Luciferase Proteins 0.000 description 1
- 239000005089 Luciferase Substances 0.000 description 1
- UPYKUZBSLRQECL-UKMVMLAPSA-N Lycopene Chemical group CC(=C/C=C/C=C(C)/C=C/C=C(C)/C=C/C1C(=C)CCCC1(C)C)C=CC=C(/C)C=CC2C(=C)CCCC2(C)C UPYKUZBSLRQECL-UKMVMLAPSA-N 0.000 description 1
- FYYHWMGAXLPEAU-UHFFFAOYSA-N Magnesium Chemical compound [Mg] FYYHWMGAXLPEAU-UHFFFAOYSA-N 0.000 description 1
- 229930195725 Mannitol Natural products 0.000 description 1
- 108010070551 Meat Proteins Proteins 0.000 description 1
- 241001465754 Metazoa Species 0.000 description 1
- 241001529936 Murinae Species 0.000 description 1
- 101100275572 Mus musculus Cyp1a1 gene Proteins 0.000 description 1
- 101100288498 Mus musculus Large1 gene Proteins 0.000 description 1
- 101001099463 Mus musculus Myeloperoxidase Proteins 0.000 description 1
- 101000605126 Mus musculus Prostaglandin G/H synthase 2 Proteins 0.000 description 1
- 101000648740 Mus musculus Tumor necrosis factor Proteins 0.000 description 1
- 108010057466 NF-kappa B Proteins 0.000 description 1
- 102000003945 NF-kappa B Human genes 0.000 description 1
- 241000588652 Neisseria gonorrhoeae Species 0.000 description 1
- 235000019482 Palm oil Nutrition 0.000 description 1
- 229920003171 Poly (ethylene oxide) Polymers 0.000 description 1
- ZLMJMSJWJFRBEC-UHFFFAOYSA-N Potassium Chemical compound [K] ZLMJMSJWJFRBEC-UHFFFAOYSA-N 0.000 description 1
- 235000019484 Rapeseed oil Nutrition 0.000 description 1
- 235000019485 Safflower oil Nutrition 0.000 description 1
- 206010039509 Scab Diseases 0.000 description 1
- BUGBHKTXTAQXES-UHFFFAOYSA-N Selenium Chemical compound [Se] BUGBHKTXTAQXES-UHFFFAOYSA-N 0.000 description 1
- 108010073771 Soybean Proteins Proteins 0.000 description 1
- 241000194017 Streptococcus Species 0.000 description 1
- 229930006000 Sucrose Natural products 0.000 description 1
- CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 description 1
- 108091023040 Transcription factor Proteins 0.000 description 1
- 102000040945 Transcription factor Human genes 0.000 description 1
- 201000006704 Ulcerative Colitis Diseases 0.000 description 1
- FPIPGXGPPPQFEQ-BOOMUCAASA-N Vitamin A Natural products OC/C=C(/C)\C=C\C=C(\C)/C=C/C1=C(C)CCCC1(C)C FPIPGXGPPPQFEQ-BOOMUCAASA-N 0.000 description 1
- 229930003270 Vitamin B Chemical group 0.000 description 1
- 229930003268 Vitamin C Natural products 0.000 description 1
- 229930003316 Vitamin D Chemical group 0.000 description 1
- QYSXJUFSXHHAJI-XFEUOLMDSA-N Vitamin D3 Chemical group C1(/[C@@H]2CC[C@@H]([C@]2(CCC1)C)[C@H](C)CCCC(C)C)=C/C=C1\C[C@@H](O)CCC1=C QYSXJUFSXHHAJI-XFEUOLMDSA-N 0.000 description 1
- 229930003427 Vitamin E Natural products 0.000 description 1
- 229930003448 Vitamin K Chemical group 0.000 description 1
- 208000027418 Wounds and injury Diseases 0.000 description 1
- HCHKCACWOHOZIP-UHFFFAOYSA-N Zinc Chemical compound [Zn] HCHKCACWOHOZIP-UHFFFAOYSA-N 0.000 description 1
- VJHCJDRQFCCTHL-UHFFFAOYSA-N acetic acid 2,3,4,5,6-pentahydroxyhexanal Chemical compound CC(O)=O.OCC(O)C(O)C(O)C(O)C=O VJHCJDRQFCCTHL-UHFFFAOYSA-N 0.000 description 1
- DPXJVFZANSGRMM-UHFFFAOYSA-N acetic acid;2,3,4,5,6-pentahydroxyhexanal;sodium Chemical compound [Na].CC(O)=O.OCC(O)C(O)C(O)C(O)C=O DPXJVFZANSGRMM-UHFFFAOYSA-N 0.000 description 1
- 230000000996 additive effect Effects 0.000 description 1
- 239000000443 aerosol Substances 0.000 description 1
- FPIPGXGPPPQFEQ-OVSJKPMPSA-N all-trans-retinol Chemical group OC\C=C(/C)\C=C\C=C(/C)\C=C\C1=C(C)CCCC1(C)C FPIPGXGPPPQFEQ-OVSJKPMPSA-N 0.000 description 1
- 239000010775 animal oil Substances 0.000 description 1
- 239000005557 antagonist Substances 0.000 description 1
- 229940124599 anti-inflammatory drug Drugs 0.000 description 1
- 229940114079 arachidonic acid Drugs 0.000 description 1
- 235000021342 arachidonic acid Nutrition 0.000 description 1
- 125000003118 aryl group Chemical group 0.000 description 1
- QVGXLLKOCUKJST-UHFFFAOYSA-N atomic oxygen Chemical compound [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 description 1
- SQVRNKJHWKZAKO-UHFFFAOYSA-N beta-N-Acetyl-D-neuraminic acid Natural products CC(=O)NC1C(O)CC(O)(C(O)=O)OC1C(O)C(O)CO SQVRNKJHWKZAKO-UHFFFAOYSA-N 0.000 description 1
- 239000011230 binding agent Substances 0.000 description 1
- 229960000074 biopharmaceutical Drugs 0.000 description 1
- 229960002685 biotin Drugs 0.000 description 1
- 235000020958 biotin Nutrition 0.000 description 1
- 239000011616 biotin Substances 0.000 description 1
- 235000015895 biscuits Nutrition 0.000 description 1
- 210000004204 blood vessel Anatomy 0.000 description 1
- 235000008429 bread Nutrition 0.000 description 1
- 239000000872 buffer Substances 0.000 description 1
- 235000014121 butter Nutrition 0.000 description 1
- 239000001768 carboxy methyl cellulose Substances 0.000 description 1
- 239000008112 carboxymethyl-cellulose Substances 0.000 description 1
- 229950008138 carmellose Drugs 0.000 description 1
- 150000001746 carotenes Chemical group 0.000 description 1
- 235000005473 carotenes Nutrition 0.000 description 1
- 239000005018 casein Substances 0.000 description 1
- BECPQYXYKAMYBN-UHFFFAOYSA-N casein, tech. Chemical compound NCCCCC(C(O)=O)N=C(O)C(CC(O)=O)N=C(O)C(CCC(O)=N)N=C(O)C(CC(C)C)N=C(O)C(CCC(O)=O)N=C(O)C(CC(O)=O)N=C(O)C(CCC(O)=O)N=C(O)C(C(C)O)N=C(O)C(CCC(O)=N)N=C(O)C(CCC(O)=N)N=C(O)C(CCC(O)=N)N=C(O)C(CCC(O)=O)N=C(O)C(CCC(O)=O)N=C(O)C(COP(O)(O)=O)N=C(O)C(CCC(O)=N)N=C(O)C(N)CC1=CC=CC=C1 BECPQYXYKAMYBN-UHFFFAOYSA-N 0.000 description 1
- 235000021240 caseins Nutrition 0.000 description 1
- 239000004359 castor oil Substances 0.000 description 1
- 235000019438 castor oil Nutrition 0.000 description 1
- 210000002390 cell membrane structure Anatomy 0.000 description 1
- 239000001913 cellulose Substances 0.000 description 1
- 229920002678 cellulose Polymers 0.000 description 1
- 235000010980 cellulose Nutrition 0.000 description 1
- 230000008859 change Effects 0.000 description 1
- 229960001231 choline Drugs 0.000 description 1
- OEYIOHPDSNJKLS-UHFFFAOYSA-N choline Chemical compound C[N+](C)(C)CCO OEYIOHPDSNJKLS-UHFFFAOYSA-N 0.000 description 1
- 239000003240 coconut oil Substances 0.000 description 1
- 235000019864 coconut oil Nutrition 0.000 description 1
- ACTIUHUUMQJHFO-UPTCCGCDSA-N coenzyme Q10 Chemical compound COC1=C(OC)C(=O)C(C\C=C(/C)CC\C=C(/C)CC\C=C(/C)CC\C=C(/C)CC\C=C(/C)CC\C=C(/C)CC\C=C(/C)CC\C=C(/C)CC\C=C(/C)CCC=C(C)C)=C(C)C1=O ACTIUHUUMQJHFO-UPTCCGCDSA-N 0.000 description 1
- 239000003086 colorant Substances 0.000 description 1
- 230000002860 competitive effect Effects 0.000 description 1
- 235000008504 concentrate Nutrition 0.000 description 1
- 239000012141 concentrate Substances 0.000 description 1
- 235000009508 confectionery Nutrition 0.000 description 1
- 238000007796 conventional method Methods 0.000 description 1
- 238000001816 cooling Methods 0.000 description 1
- 229910052802 copper Inorganic materials 0.000 description 1
- 239000010949 copper Substances 0.000 description 1
- 235000005687 corn oil Nutrition 0.000 description 1
- 239000002285 corn oil Substances 0.000 description 1
- 239000008120 corn starch Substances 0.000 description 1
- 235000012495 crackers Nutrition 0.000 description 1
- 239000006071 cream Substances 0.000 description 1
- 210000000805 cytoplasm Anatomy 0.000 description 1
- 230000006378 damage Effects 0.000 description 1
- 238000011161 development Methods 0.000 description 1
- 235000019425 dextrin Nutrition 0.000 description 1
- 235000013325 dietary fiber Nutrition 0.000 description 1
- CRVGKGJPQYZRPT-UHFFFAOYSA-N diethylamino acetate Chemical compound CCN(CC)OC(C)=O CRVGKGJPQYZRPT-UHFFFAOYSA-N 0.000 description 1
- 230000029087 digestion Effects 0.000 description 1
- 239000003085 diluting agent Substances 0.000 description 1
- 238000010790 dilution Methods 0.000 description 1
- 239000012895 dilution Substances 0.000 description 1
- 239000007884 disintegrant Substances 0.000 description 1
- 238000004821 distillation Methods 0.000 description 1
- 239000012153 distilled water Substances 0.000 description 1
- 238000002036 drum drying Methods 0.000 description 1
- 230000002884 effect on inflammation Effects 0.000 description 1
- 239000006274 endogenous ligand Substances 0.000 description 1
- 150000002148 esters Chemical class 0.000 description 1
- 230000003203 everyday effect Effects 0.000 description 1
- 230000005713 exacerbation Effects 0.000 description 1
- 230000001747 exhibiting effect Effects 0.000 description 1
- 239000003889 eye drop Substances 0.000 description 1
- 229940012356 eye drops Drugs 0.000 description 1
- 239000003885 eye ointment Substances 0.000 description 1
- 235000021323 fish oil Nutrition 0.000 description 1
- 239000012530 fluid Substances 0.000 description 1
- 235000013373 food additive Nutrition 0.000 description 1
- 239000002778 food additive Substances 0.000 description 1
- 235000011194 food seasoning agent Nutrition 0.000 description 1
- 235000013350 formula milk Nutrition 0.000 description 1
- 239000003205 fragrance Substances 0.000 description 1
- 238000004108 freeze drying Methods 0.000 description 1
- 235000013611 frozen food Nutrition 0.000 description 1
- 235000011306 frozen processed food Nutrition 0.000 description 1
- 235000013376 functional food Nutrition 0.000 description 1
- WIGCFUFOHFEKBI-UHFFFAOYSA-N gamma-tocopherol Natural products CC(C)CCCC(C)CCCC(C)CCCC1CCC2C(C)C(O)C(C)C(C)C2O1 WIGCFUFOHFEKBI-UHFFFAOYSA-N 0.000 description 1
- 210000004211 gastric acid Anatomy 0.000 description 1
- 230000002496 gastric effect Effects 0.000 description 1
- 239000008273 gelatin Substances 0.000 description 1
- 229920000159 gelatin Polymers 0.000 description 1
- 235000019322 gelatine Nutrition 0.000 description 1
- 235000011852 gelatine desserts Nutrition 0.000 description 1
- 239000011521 glass Substances 0.000 description 1
- ZEMPKEQAKRGZGQ-XOQCFJPHSA-N glycerol triricinoleate Natural products CCCCCC[C@@H](O)CC=CCCCCCCCC(=O)OC[C@@H](COC(=O)CCCCCCCC=CC[C@@H](O)CCCCCC)OC(=O)CCCCCCCC=CC[C@H](O)CCCCCC ZEMPKEQAKRGZGQ-XOQCFJPHSA-N 0.000 description 1
- 239000007952 growth promoter Substances 0.000 description 1
- 230000036541 health Effects 0.000 description 1
- 235000013402 health food Nutrition 0.000 description 1
- 206010073071 hepatocellular carcinoma Diseases 0.000 description 1
- 239000000833 heterodimer Substances 0.000 description 1
- 230000013632 homeostatic process Effects 0.000 description 1
- 102000052268 human CYP1A1 Human genes 0.000 description 1
- 239000001863 hydroxypropyl cellulose Substances 0.000 description 1
- 235000010977 hydroxypropyl cellulose Nutrition 0.000 description 1
- 239000001866 hydroxypropyl methyl cellulose Substances 0.000 description 1
- 235000010979 hydroxypropyl methyl cellulose Nutrition 0.000 description 1
- 229920003088 hydroxypropyl methyl cellulose Polymers 0.000 description 1
- UFVKGYZPFZQRLF-UHFFFAOYSA-N hydroxypropyl methyl cellulose Chemical compound OC1C(O)C(OC)OC(CO)C1OC1C(O)C(O)C(OC2C(C(O)C(OC3C(C(O)C(O)C(CO)O3)O)C(CO)O2)O)C(CO)O1 UFVKGYZPFZQRLF-UHFFFAOYSA-N 0.000 description 1
- 238000011534 incubation Methods 0.000 description 1
- 230000028709 inflammatory response Effects 0.000 description 1
- 239000004615 ingredient Substances 0.000 description 1
- 230000005764 inhibitory process Effects 0.000 description 1
- 208000014674 injury Diseases 0.000 description 1
- 229960000367 inositol Drugs 0.000 description 1
- CDAISMWEOUEBRE-GPIVLXJGSA-N inositol Chemical compound O[C@H]1[C@H](O)[C@@H](O)[C@H](O)[C@H](O)[C@@H]1O CDAISMWEOUEBRE-GPIVLXJGSA-N 0.000 description 1
- 229910052742 iron Inorganic materials 0.000 description 1
- 239000007951 isotonicity adjuster Substances 0.000 description 1
- 235000015110 jellies Nutrition 0.000 description 1
- 239000008274 jelly Substances 0.000 description 1
- CSSYQJWUGATIHM-IKGCZBKSSA-N l-phenylalanyl-l-lysyl-l-cysteinyl-l-arginyl-l-arginyl-l-tryptophyl-l-glutaminyl-l-tryptophyl-l-arginyl-l-methionyl-l-lysyl-l-lysyl-l-leucylglycyl-l-alanyl-l-prolyl-l-seryl-l-isoleucyl-l-threonyl-l-cysteinyl-l-valyl-l-arginyl-l-arginyl-l-alanyl-l-phenylal Chemical compound C([C@H](N)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CS)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CC=1C2=CC=CC=C2NC=1)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CC=1C2=CC=CC=C2NC=1)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CCSC)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CC(C)C)C(=O)NCC(=O)N[C@@H](C)C(=O)N1CCC[C@H]1C(=O)N[C@@H](CO)C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CS)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](C)C(=O)N[C@@H](CC=1C=CC=CC=1)C(O)=O)C1=CC=CC=C1 CSSYQJWUGATIHM-IKGCZBKSSA-N 0.000 description 1
- 229940039696 lactobacillus Drugs 0.000 description 1
- 235000021242 lactoferrin Nutrition 0.000 description 1
- 229940078795 lactoferrin Drugs 0.000 description 1
- 239000000865 liniment Substances 0.000 description 1
- 210000004185 liver Anatomy 0.000 description 1
- 239000006210 lotion Substances 0.000 description 1
- 239000007937 lozenge Substances 0.000 description 1
- 239000000314 lubricant Substances 0.000 description 1
- 238000004020 luminiscence type Methods 0.000 description 1
- 210000005265 lung cell Anatomy 0.000 description 1
- 239000011777 magnesium Substances 0.000 description 1
- 229910052749 magnesium Inorganic materials 0.000 description 1
- WPBNNNQJVZRUHP-UHFFFAOYSA-L manganese(2+);methyl n-[[2-(methoxycarbonylcarbamothioylamino)phenyl]carbamothioyl]carbamate;n-[2-(sulfidocarbothioylamino)ethyl]carbamodithioate Chemical compound [Mn+2].[S-]C(=S)NCCNC([S-])=S.COC(=O)NC(=S)NC1=CC=CC=C1NC(=S)NC(=O)OC WPBNNNQJVZRUHP-UHFFFAOYSA-L 0.000 description 1
- 239000000594 mannitol Substances 0.000 description 1
- 235000010355 mannitol Nutrition 0.000 description 1
- 239000003550 marker Substances 0.000 description 1
- 239000000463 material Substances 0.000 description 1
- 238000005259 measurement Methods 0.000 description 1
- 238000000691 measurement method Methods 0.000 description 1
- 230000007246 mechanism Effects 0.000 description 1
- 150000004667 medium chain fatty acids Chemical class 0.000 description 1
- 108020004999 messenger RNA Proteins 0.000 description 1
- 230000000877 morphologic effect Effects 0.000 description 1
- 210000000214 mouth Anatomy 0.000 description 1
- 210000004400 mucous membrane Anatomy 0.000 description 1
- 230000035772 mutation Effects 0.000 description 1
- 229910052757 nitrogen Inorganic materials 0.000 description 1
- 239000000041 non-steroidal anti-inflammatory agent Substances 0.000 description 1
- 229940021182 non-steroidal anti-inflammatory drug Drugs 0.000 description 1
- 230000035764 nutrition Effects 0.000 description 1
- 239000002674 ointment Substances 0.000 description 1
- 210000000056 organ Anatomy 0.000 description 1
- 210000004798 organs belonging to the digestive system Anatomy 0.000 description 1
- 239000001254 oxidized starch Substances 0.000 description 1
- 235000013808 oxidized starch Nutrition 0.000 description 1
- 229910052760 oxygen Inorganic materials 0.000 description 1
- 239000001301 oxygen Substances 0.000 description 1
- 239000002540 palm oil Substances 0.000 description 1
- 229940055726 pantothenic acid Drugs 0.000 description 1
- 235000019161 pantothenic acid Nutrition 0.000 description 1
- 239000011713 pantothenic acid Substances 0.000 description 1
- 230000037361 pathway Effects 0.000 description 1
- 239000002304 perfume Substances 0.000 description 1
- 150000003904 phospholipids Chemical class 0.000 description 1
- SHUZOJHMOBOZST-UHFFFAOYSA-N phylloquinone Chemical group CC(C)CCCCC(C)CCC(C)CCCC(=CCC1=C(C)C(=O)c2ccccc2C1=O)C SHUZOJHMOBOZST-UHFFFAOYSA-N 0.000 description 1
- 230000001766 physiological effect Effects 0.000 description 1
- 235000013550 pizza Nutrition 0.000 description 1
- 239000001267 polyvinylpyrrolidone Substances 0.000 description 1
- 229920000036 polyvinylpyrrolidone Polymers 0.000 description 1
- 235000013855 polyvinylpyrrolidone Nutrition 0.000 description 1
- 230000029279 positive regulation of transcription, DNA-dependent Effects 0.000 description 1
- 239000011591 potassium Substances 0.000 description 1
- 229910052700 potassium Inorganic materials 0.000 description 1
- 238000011533 pre-incubation Methods 0.000 description 1
- 239000003755 preservative agent Substances 0.000 description 1
- 230000002265 prevention Effects 0.000 description 1
- 230000008569 process Effects 0.000 description 1
- 238000012545 processing Methods 0.000 description 1
- 230000035755 proliferation Effects 0.000 description 1
- 238000011002 quantification Methods 0.000 description 1
- 230000000241 respiratory effect Effects 0.000 description 1
- IKGXIBQEEMLURG-NVPNHPEKSA-N rutin Chemical compound O[C@@H]1[C@H](O)[C@@H](O)[C@H](C)O[C@H]1OC[C@@H]1[C@@H](O)[C@H](O)[C@@H](O)[C@H](OC=2C(C3=C(O)C=C(O)C=C3OC=2C=2C=C(O)C(O)=CC=2)=O)O1 IKGXIBQEEMLURG-NVPNHPEKSA-N 0.000 description 1
- 235000005713 safflower oil Nutrition 0.000 description 1
- 239000003813 safflower oil Substances 0.000 description 1
- 150000003839 salts Chemical class 0.000 description 1
- CDAISMWEOUEBRE-UHFFFAOYSA-N scyllo-inosotol Natural products OC1C(O)C(O)C(O)C(O)C1O CDAISMWEOUEBRE-UHFFFAOYSA-N 0.000 description 1
- 229910052711 selenium Inorganic materials 0.000 description 1
- 239000011669 selenium Substances 0.000 description 1
- 238000004904 shortening Methods 0.000 description 1
- SQVRNKJHWKZAKO-OQPLDHBCSA-N sialic acid Chemical compound CC(=O)N[C@@H]1[C@@H](O)C[C@@](O)(C(O)=O)OC1[C@H](O)[C@H](O)CO SQVRNKJHWKZAKO-OQPLDHBCSA-N 0.000 description 1
- RMAQACBXLXPBSY-UHFFFAOYSA-N silicic acid Chemical compound O[Si](O)(O)O RMAQACBXLXPBSY-UHFFFAOYSA-N 0.000 description 1
- 235000012239 silicon dioxide Nutrition 0.000 description 1
- 210000003491 skin Anatomy 0.000 description 1
- 238000002791 soaking Methods 0.000 description 1
- 239000011734 sodium Substances 0.000 description 1
- 229910052708 sodium Inorganic materials 0.000 description 1
- 235000014214 soft drink Nutrition 0.000 description 1
- 239000002904 solvent Substances 0.000 description 1
- 229940001941 soy protein Drugs 0.000 description 1
- 241000894007 species Species 0.000 description 1
- 235000015096 spirit Nutrition 0.000 description 1
- 238000001694 spray drying Methods 0.000 description 1
- 239000003381 stabilizer Substances 0.000 description 1
- 230000001954 sterilising effect Effects 0.000 description 1
- 150000003431 steroids Chemical class 0.000 description 1
- 210000002784 stomach Anatomy 0.000 description 1
- 239000005720 sucrose Substances 0.000 description 1
- 239000000829 suppository Substances 0.000 description 1
- 239000004094 surface-active agent Substances 0.000 description 1
- 238000001356 surgical procedure Methods 0.000 description 1
- 239000000375 suspending agent Substances 0.000 description 1
- 238000002636 symptomatic treatment Methods 0.000 description 1
- 230000009885 systemic effect Effects 0.000 description 1
- 230000001225 therapeutic effect Effects 0.000 description 1
- 210000001519 tissue Anatomy 0.000 description 1
- 231100000331 toxic Toxicity 0.000 description 1
- 230000002588 toxic effect Effects 0.000 description 1
- 230000002103 transcriptional effect Effects 0.000 description 1
- UFTFJSFQGQCHQW-UHFFFAOYSA-N triformin Chemical compound O=COCC(OC=O)COC=O UFTFJSFQGQCHQW-UHFFFAOYSA-N 0.000 description 1
- 229960004747 ubidecarenone Drugs 0.000 description 1
- 210000004291 uterus Anatomy 0.000 description 1
- 238000001291 vacuum drying Methods 0.000 description 1
- 235000015112 vegetable and seed oil Nutrition 0.000 description 1
- 239000008158 vegetable oil Substances 0.000 description 1
- 230000035899 viability Effects 0.000 description 1
- 235000019155 vitamin A Nutrition 0.000 description 1
- 239000011719 vitamin A Substances 0.000 description 1
- NCYCYZXNIZJOKI-UHFFFAOYSA-N vitamin A aldehyde Chemical group O=CC=C(C)C=CC=C(C)C=CC1=C(C)CCCC1(C)C NCYCYZXNIZJOKI-UHFFFAOYSA-N 0.000 description 1
- 235000019156 vitamin B Nutrition 0.000 description 1
- 239000011720 vitamin B Chemical group 0.000 description 1
- 235000019154 vitamin C Nutrition 0.000 description 1
- 239000011718 vitamin C Substances 0.000 description 1
- 235000019166 vitamin D Nutrition 0.000 description 1
- 239000011710 vitamin D Chemical group 0.000 description 1
- 150000003710 vitamin D derivatives Chemical group 0.000 description 1
- 235000019165 vitamin E Nutrition 0.000 description 1
- 229940046009 vitamin E Drugs 0.000 description 1
- 239000011709 vitamin E Substances 0.000 description 1
- 235000019168 vitamin K Nutrition 0.000 description 1
- 239000011712 vitamin K Chemical group 0.000 description 1
- 150000003721 vitamin K derivatives Chemical group 0.000 description 1
- 229940045997 vitamin a Drugs 0.000 description 1
- 229940046008 vitamin d Drugs 0.000 description 1
- 229940046010 vitamin k Drugs 0.000 description 1
- 230000004584 weight gain Effects 0.000 description 1
- 235000019786 weight gain Nutrition 0.000 description 1
- 230000004580 weight loss Effects 0.000 description 1
- 235000008939 whole milk Nutrition 0.000 description 1
- 239000011701 zinc Substances 0.000 description 1
- 229910052725 zinc Inorganic materials 0.000 description 1
- 235000021249 α-casein Nutrition 0.000 description 1
- 235000021241 α-lactalbumin Nutrition 0.000 description 1
- 235000021247 β-casein Nutrition 0.000 description 1
- 235000021246 κ-casein Nutrition 0.000 description 1
Images
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
- A61K35/66—Microorganisms or materials therefrom
- A61K35/74—Bacteria
- A61K35/741—Probiotics
- A61K35/744—Lactic acid bacteria, e.g. enterococci, pediococci, lactococci, streptococci or leuconostocs
- A61K35/747—Lactobacilli, e.g. L. acidophilus or L. brevis
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23C—DAIRY PRODUCTS, e.g. MILK, BUTTER OR CHEESE; MILK OR CHEESE SUBSTITUTES; MAKING THEREOF
- A23C9/00—Milk preparations; Milk powder or milk powder preparations
- A23C9/12—Fermented milk preparations; Treatment using microorganisms or enzymes
- A23C9/123—Fermented milk preparations; Treatment using microorganisms or enzymes using only microorganisms of the genus lactobacteriaceae; Yoghurt
- A23C9/1238—Fermented milk preparations; Treatment using microorganisms or enzymes using only microorganisms of the genus lactobacteriaceae; Yoghurt using specific L. bulgaricus or S. thermophilus microorganisms; using entrapped or encapsulated yoghurt bacteria; Physical or chemical treatment of L. bulgaricus or S. thermophilus cultures; Fermentation only with L. bulgaricus or only with S. thermophilus
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23K—FODDER
- A23K10/00—Animal feeding-stuffs
- A23K10/10—Animal feeding-stuffs obtained by microbiological or biochemical processes
- A23K10/16—Addition of microorganisms or extracts thereof, e.g. single-cell proteins, to feeding-stuff compositions
- A23K10/18—Addition of microorganisms or extracts thereof, e.g. single-cell proteins, to feeding-stuff compositions of live microorganisms
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
- A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
- A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
- A23L33/135—Bacteria or derivatives thereof, e.g. probiotics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
- A61K31/19—Carboxylic acids, e.g. valproic acid
- A61K31/192—Carboxylic acids, e.g. valproic acid having aromatic groups, e.g. sulindac, 2-aryl-propionic acids, ethacrynic acid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
- A61K35/66—Microorganisms or materials therefrom
- A61K35/74—Bacteria
- A61K35/741—Probiotics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
- A61K35/66—Microorganisms or materials therefrom
- A61K35/74—Bacteria
- A61K35/741—Probiotics
- A61K35/744—Lactic acid bacteria, e.g. enterococci, pediococci, lactococci, streptococci or leuconostocs
- A61K35/745—Bifidobacteria
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N1/00—Microorganisms, e.g. protozoa; Compositions thereof; Processes of propagating, maintaining or preserving microorganisms or compositions thereof; Processes of preparing or isolating a composition containing a microorganism; Culture media therefor
- C12N1/20—Bacteria; Culture media therefor
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N1/00—Microorganisms, e.g. protozoa; Compositions thereof; Processes of propagating, maintaining or preserving microorganisms or compositions thereof; Processes of preparing or isolating a composition containing a microorganism; Culture media therefor
- C12N1/20—Bacteria; Culture media therefor
- C12N1/205—Bacterial isolates
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
- C12Q1/02—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving viable microorganisms
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
- C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
- C12Q1/6897—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids involving reporter genes operably linked to promoters
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
- A23V2002/00—Food compositions, function of food ingredients or processes for food or foodstuffs
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
- A23V2200/00—Function of food ingredients
- A23V2200/30—Foods, ingredients or supplements having a functional effect on health
- A23V2200/32—Foods, ingredients or supplements having a functional effect on health having an effect on the health of the digestive tract
- A23V2200/3204—Probiotics, living bacteria to be ingested for action in the digestive tract
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
- A23V2400/00—Lactic or propionic acid bacteria
- A23V2400/11—Lactobacillus
- A23V2400/123—Bulgaricus
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
- A23V2400/00—Lactic or propionic acid bacteria
- A23V2400/11—Lactobacillus
- A23V2400/137—Delbrueckii
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
- A23V2400/00—Lactic or propionic acid bacteria
- A23V2400/21—Streptococcus, lactococcus
- A23V2400/249—Thermophilus
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12R—INDEXING SCHEME ASSOCIATED WITH SUBCLASSES C12C - C12Q, RELATING TO MICROORGANISMS
- C12R2001/00—Microorganisms ; Processes using microorganisms
- C12R2001/01—Bacteria or Actinomycetales ; using bacteria or Actinomycetales
- C12R2001/225—Lactobacillus
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2500/00—Screening for compounds of potential therapeutic value
- G01N2500/10—Screening for compounds of potential therapeutic value involving cells
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2800/00—Detection or diagnosis of diseases
- G01N2800/06—Gastro-intestinal diseases
Definitions
- the present invention relates to probiotics and novel strains that exert an anti-inflammatory action in the intestine by activating aromatic hydrocarbon receptors (AhR), compositions for oral consumption containing the probiotics and strains, and
- the present invention relates to the probiotics and strain screening methods.
- antibiotics antibiotics
- problems such as the side effects of antibiotics and the emergence of multidrug-resistant bacteria due to mutations have become a hot topic. Therefore, the idea of “probiotics” has recently been widely recognized for “antibiotics”.
- Probiotics are "useful microorganisms that can improve the bacterial flora in the gastrointestinal tract and bring about beneficial effects on the host, and their growth promoters.” The idea of preventing and improving diseases while acting on flora (bacteria flora) in the oral cavity and intestine and making flora healthy is born.
- the aromatic hydrocarbon receptor is a transcription factor belonging to the bHLH-PAS family, which is expressed in most cells and tissues, and causes transcriptional activation of various genes through the binding of ligands. It has been known. Compounds such as dioxins and polychlorinated biphenyls are known as AhR ligands, but endogenous ligands are unknown receptors.
- AhR in a state not bound to a ligand is inactive and exists in the cytoplasm in a state associated with a molecular chaperone such as Hsp90.
- a molecular chaperone such as Hsp90.
- the molecular chaperone is dissociated, and the activated AhR moves into the nucleus.
- the AhR transferred into the nucleus binds to a molecule called ARNT (AhR Nuclear Translocator) to form a heterodimer and interacts with an enhancer sequence called Xenopic responsive element (XRE) on DNA. This activates transcription of downstream genes.
- ARNT AhR Nuclear Translocator
- XRE Xenopic responsive element
- TCDD 2,3,7,8-tetrachlorodibenzo-p-dioxin
- DSS dextran sulfate sodium
- An object of the present invention is to provide a probiotic capable of suppressing inflammatory injury in the digestive tract by activating AhR.
- the present invention relates to the following.
- Lactobacillus delbrueckii subsp. Bulgaricus OLL1181 strain accesion number: FERM BP-11269).
- An anti-inflammatory agent comprising probiotics having AhR activation ability.
- composition for oral consumption comprising the anti-inflammatory agent according to any one of (5) to (8).
- composition for oral intake according to (9), wherein the composition for oral intake is selected from the group consisting of a beverage composition, a food composition, a feed composition and a pharmaceutical composition.
- AhR activation ability comprising a step of stimulating AhR-expressing cells having a foreign substance response element (XRE) and a reporter gene region downstream thereof with candidate probiotics and / or culture supernatants thereof A method for screening probiotics.
- XRE foreign substance response element
- an anti-inflammatory agent that can be safely ingested orally and can act anti-inflammatory in the digestive tract with few side effects can be produced by activating AhR. Furthermore, since the probiotic of the present invention has a clear action point that it can induce an anti-inflammatory action by acting on AhR, it can be expected to have a very high effect and is selected by the screening method of the present invention. Any of the probiotics to be used can be expected to have high ability in terms of anti-inflammatory action through AhR activation.
- the anti-inflammatory action of the probiotics of the present invention can be used for long-term treatment in intractable diseases such as inflammatory bowel disease, which was difficult from the viewpoint of side effects of conventional anti-inflammatory agents.
- intractable diseases such as inflammatory bowel disease
- fundamental treatment is possible by improving the constitution by utilizing homeostasis of the living body. It shows a new possibility of being.
- FIG. 1 shows the results of screening various lactic acid bacteria by the screening method of the present invention.
- No treat represents a negative control and Posicon represents a positive control.
- FIG. 2 shows the results of SEAP activity in the culture supernatant of HeXS34 cells stimulated with the strain OLL1181 of the present invention.
- FIG. 3 shows the relative expression level of CYP1A1 in Caco2 cells stimulated with the OLL1181 strain of the present invention. As a comparison, the relative expression level when stimulated with MEP222701 strain and ⁇ NF alone is shown together.
- FIG. 4 shows the relative expression level of CYP1A1 in the in vivo colon when the strain OLL1181 of the present invention was administered to mice.
- FIG. 5 shows A: relative expression level of COX-2 in human Caco2 cells, B: relative expression level of COX-2 in vivo in mouse colon, and C: human when stimulated with the strain OLL1181 of the present invention. The amount of secretion of PGE2 in the culture supernatant of Caco2 cells is represented.
- FIG. 6 shows the experimental results of verifying the effect of the strain OLL1181 of the present invention on DSS-induced enteritis.
- D large intestine of each test group on the 11th day Represents the relative expression level of TNF- ⁇ and MPO.
- the present invention relates to a probiotic having an ability to activate an aromatic hydrocarbon receptor (AhR).
- AhR activation ability refers to the ability to activate a signal transduction pathway initiated by AhR activation, and any activation mechanism may be used. Therefore, the cells themselves do not necessarily need to be AhR ligands. For example, secreted substances produced by the cells may have AhR activation ability, or AhR may be activated by dead cells or their disruptions. May be. Therefore, in the present invention, the term “microorganism”, “bacteria”, or a specific bacterium includes not only a living bacterium itself, but also dead cells or a crushed product thereof, and a culture or secretion of the bacterium. However, it is preferably a living cell itself such as a living cell, a dead cell or a crushed product thereof, and more preferably a living cell from the viewpoint that a bacterial flora can be formed in the digestive tract.
- probiotic refers to “a useful microorganism that can improve the bacterial flora in the digestive tract and have a beneficial effect on the host and their growth promoting substances” as described above. Accordingly, the probiotics of the present invention include not only bacteria that form a bacterial flora, but also substances that promote the growth of such bacteria.
- the term “probiotic” includes useful microorganisms that can bring about beneficial effects on the host and substances produced by these microorganisms (culture of microorganisms). Even if the substance itself has AhR activation ability, the substance itself does not have AhR activation ability, but the growth of bacteria having AhR activation ability can be prevented. It also includes the case of promoting.
- the probiotic is preferably a viable microorganism because it can form a suitable intestinal environment and the action does not depend on individual differences in the intestinal environment, but temporary AhR activation is desired. In some cases, dead cells and bacterial secretions are preferred.
- Examples of the bacterium included in the probiotics of the present invention include, but are not limited to, lactic acid bacteria, bifidobacteria, propionic acid bacteria, bacteroides, eubacterium, anaerobic streptococci, enterococci, and E. coli. It is done. However, from the viewpoint of safety and the like, lactic acid bacteria, bifidobacteria and propionic acid bacteria are preferable, and lactic acid bacteria and bifidobacteria are more preferable. Among these, lactic acid bacteria are more preferable from the viewpoint that the cells themselves have AhR activation ability and that not only live cells but also dead cells can activate AhR. Among lactic acid bacteria, Lactobacillus bulgaricus, Streptococcus usthermophilus, and the like are particularly preferable from the viewpoint that they are used for the production of yogurt and can be easily applied as food.
- Lactobacillus delbrueckiiecksubsp.spbulgaricus OL1181 strain (Accession No .: FERM BP-11269) was isolated as a novel probiotic having AhR activation ability. Accordingly, in one embodiment of the present invention, the probiotics of the present invention include Lactobacillus delbrueckii subsp. Bulgaricus LOLL1181 strain.
- the OLL1181 strain of the present invention is registered with the National Institute of Advanced Industrial Science and Technology Patent Biological Deposit Center (1st, 1st, 1st East, 1-chome, Tsukuba City, Ibaraki, Japan, 305-8586) on July 16, 2010. : A novel Lactobacillus delbrueckii subsp. Bulgaricus strain deposited as FERM BP-11269 and having the following characteristics.
- (A) Morphological properties Neisseria gonorrhoeae (b) Culture properties Medium name: Lactobacilli MRS Broth (Difco, Ref. No.
- the OLL1181 strain activates AhR and increases the production of PGE2 downstream of its signal transduction pathway, and as a result, can exhibit an anti-inflammatory effect in the digestive tract.
- the present inventors have found that OLL1181 strain has AhR activation ability in both living and dead cells. It is a surprising discovery that the cells of OLL1181 strain, which is a Gram-positive bacterium without LPS, have AhR activation ability.
- the OLL1181 strain is Lactobacillus delbrueckii subsp. Bulgaricus and is a safe bacterium that does not have biotoxicity. Therefore, it can be used for various uses including compositions for oral intake such as food compositions and beverage compositions. It is very useful as a probiotic because it can be used.
- the OLL1181 strain itself can activate AhR, it can exhibit AhR activation ability regardless of the viability of the fungus contained in the composition. Therefore, it is also very useful in that it can be included in various compositions.
- the probiotics of the present invention have AhR activation ability, and can activate the production of PGE2 by activating AhR, thereby exhibiting anti-inflammatory effects. Therefore, the probiotic of the present invention can be used as an active ingredient of an anti-inflammatory agent.
- the probiotic of the present invention is used as an active ingredient of an anti-inflammatory agent
- live bacteria, dead bacteria, cultures, processed products thereof, and combinations thereof can be used.
- the culture uses the culture supernatant and medium components after completion of the culture of the probiotic of the present invention as it is, and the processed product is not particularly limited as long as it is derived from the culture. And the like obtained by processing such as concentration, pasting, spray drying, freeze drying, vacuum drying, drum drying, liquefaction, dilution and crushing.
- the anti-inflammatory agent includes, but is not limited to, any pharmacologically acceptable carrier, excipient, additive, diluent and the like. Ingredients may further be included.
- probiotics of the present invention cultures thereof, or processed products thereof are appropriately provided with, for example, medium components, additives suitable for oral tube feeding, solvents such as water, carbohydrates, proteins, lipids, vitamins Biopharmaceutical trace metals, fragrances, pharmaceutically acceptable carriers, food additives, and other optional components can be added to form pharmaceutical compositions and food compositions.
- the anti-inflammatory agent of the present invention can exert an anti-inflammatory effect due to the promotion of production of PGE2, and therefore the anti-inflammatory agent of the present invention is used for the treatment, amelioration and / or prevention of inflammatory diseases.
- Such an inflammatory disease may be any inflammatory disease, but it is preferable from the viewpoint that the effect of probiotics, which are active ingredients, can be maximized, that is, the action on local inflammation and the effect of improving other exacerbation factors.
- it is used for inflammation of the digestive tract such as inflammatory bowel disease.
- Probiotics that can be contained in the anti-inflammatory agent of the present invention are preferably lactic acid bacteria, bifidobacteria and propionic acid bacteria from the viewpoint of ease of oral intake and the magnitude of the action effect on bacterial flora in the digestive tract. More preferred are lactic acid bacteria and bifidobacteria. From the viewpoint of the effect of AhR activation possessed by the fungus body itself, lactic acid bacteria are more preferable, and Lactobacillus delbrueckii subsp. Bulgaricus OLL1181 strain is most preferable.
- the anti-inflammatory agent of the present invention exerts a symptomatic effect on inflammation in the digestive tract, particularly the intestine, by acting on cells in the digestive tract, and further acts on the bacterial flora in the digestive tract to fundamentally treat It is preferable to be taken orally because it is an agent that can exert its effect. Therefore, the composition for oral intake containing the anti-inflammatory agent of the present invention is also included in the present invention.
- the daily intake of the probiotic, the anti-inflammatory agent or the composition for oral intake of the present invention is not particularly limited, but can be appropriately adjusted according to age, symptoms, body weight, use and the like.
- the probiotic is 0.01 to 100 ⁇ 10 11 pieces / body, preferably 0.1 to 10 ⁇ 10 11 pieces / body, more preferably 0.3 to 5 ⁇ 10 11 pieces / body.
- Daily intake can be exemplified.
- 0.01 to 100 ⁇ 10 11 pieces / 60 kg body weight preferably 0.1 to 10 ⁇ 10 11 pieces / 60 kg body weight, more preferably 0.3 to 5 ⁇ 10 11 pieces / 60 kg body weight.
- Daily intake can also be exemplified.
- the intake of the probiotic, the anti-inflammatory agent or the composition for oral intake of the present invention is not limited to the above-mentioned values.
- the content of the probiotic contained in the anti-inflammatory agent or the composition for oral intake of the present invention can be appropriately determined depending on the usage form. Typically, 5 to 50 w / w%, preferably 1 to 75 w / w%, more preferably 0.1 to 100 w / w% and 1 to 100 w / w% as dry probiotic cells Can do. However, the content of the probiotic contained in the anti-inflammatory agent or the composition for oral intake of the present invention is not limited to the above-mentioned values.
- composition for oral consumption means all compositions that can be taken orally. Accordingly, the composition for ingestion includes, but is not limited to, for example, a beverage composition, a food composition, a feed composition, a pharmaceutical composition, and the like.
- the beverage composition of the present invention typically contains one or more selected from probiotics having AhR activation ability, cultures thereof and processed products thereof.
- the beverage composition of the present invention further includes carbohydrates, proteins, lipids, vitamins, essential biological trace metals (such as manganese sulfate, zinc sulfate, magnesium chloride, and potassium carbonate) as long as they do not hinder the growth of probiotics. Perfumes and other blends can be included.
- Such a beverage composition improves the intestinal environment of the ingested individual, and has an effect of improving and / or preventing inflammatory diseases.
- the food composition of the present invention typically contains one or more selected from probiotics having AhR activation ability, cultures thereof and processed products thereof.
- the food composition of the present invention further includes carbohydrates, proteins, lipids, vitamins, essential biological trace metals (manganese sulfate, zinc sulfate, magnesium chloride, potassium carbonate, etc.), flavors, and so on, as long as they do not interfere with the growth of probiotics. And other blends.
- Such a food composition improves the intestinal environment of the ingested individual, and has an effect of improving and / or preventing inflammatory diseases.
- saccharide examples include saccharides, processed starch (in addition to dextrin, soluble starch, British starch, oxidized starch, starch ester, starch ether, etc.), dietary fiber, and the like.
- protein examples include whole milk powder, skim milk powder, partially skimmed milk powder, casein, whey powder, whey protein, whey protein concentrate, whey protein isolate, ⁇ -casein, ⁇ -casein, ⁇ -casein, ⁇ -lactoglobulin , ⁇ -lactalbumin, lactoferrin, soy protein, egg protein, meat protein and other animal and vegetable proteins, hydrolysates thereof; butter, milk minerals, cream, whey, non-protein nitrogen, sialic acid, phospholipid, lactose, etc. And various milk-derived components.
- Examples of lipids include animal oils such as lard and fish oil, fractionated oils thereof, hydrogenated oils and transesterified oils; palm oil, safflower oil, corn oil, rapeseed oil, coconut oil, fractionated oils thereof, Examples include vegetable oils such as hydrogenated oils and transesterified oils.
- vitamins include vitamin A, carotene, vitamin B group, vitamin C, vitamin D group, vitamin E, vitamin K group, vitamin P, vitamin Q, niacin, nicotinic acid, pantothenic acid, biotin, inositol, choline.
- Examples of minerals include calcium, potassium, magnesium, sodium, copper, iron, manganese, zinc, and selenium.
- beverage composition and food composition of the present invention may be a functional food, a food for specific health use, a food for specific use, a functional nutrition food, a health food, a food for care, and a confectionery, It may be a lactic acid bacteria beverage, a dairy product such as cheese or yogurt, or a seasoning.
- the shape of the food and drink there is no limitation on the shape of the food and drink, and it can take any form of food or drink that can be distributed normally, such as solid, liquid, liquid food, jelly, tablet, granule, capsule, and various foods (milk, Soft drinks, fermented milk, yogurt, cheese, bread, biscuits, crackers, pizza crusts, formula milk, liquid foods, food for the sick, nutritional foods, frozen foods, processed foods and other commercial foods) .
- Manufacture of the said food / beverage products can be performed by those skilled in the art.
- the probiotics, cultures or processed products thereof of the present invention can be processed into general foods and drinks including dairy products and fermented milk, as well as starters for producing dairy products and fermented milk such as yogurt and cheese. It is also possible to use as.
- a starter other microorganisms may be mixed as long as there is no hindrance to the survival and proliferation of the probiotics of the present invention and no hindrance to dairy production.
- it may be mixed with Lactobacillus delbrueckii subsp. can do.
- Production of dairy products and fermented milk using the starter can be performed according to a conventional method.
- plain yogurt can be produced by mixing the above starter with milk or a dairy product cooled after heating, mixing, homogenizing, and sterilizing, and then fermenting and cooling.
- the feed composition of the present invention typically contains one or more selected from probiotics having AhR activation ability, cultures thereof and processed products thereof.
- the feed composition of the present invention further includes carbohydrates, proteins, lipids, vitamins, essential biological trace metals (such as manganese sulfate, zinc sulfate, magnesium chloride, and potassium carbonate), flavors, and so on, as long as they do not hinder the growth of probiotics. And other blends.
- Such a feed composition improves the intestinal environment of the ingested individual and has an effect of improving and / or preventing inflammatory diseases.
- the pharmaceutical composition of the present invention typically comprises one or more selected from probiotics having AhR activation ability, cultures thereof and processed products thereof. Such a pharmaceutical composition improves the intestinal environment of an ingested individual and has a therapeutic, ameliorating and / or preventing effect on inflammatory diseases.
- the route of administration of the pharmaceutical composition is not particularly limited, and includes oral or parenteral administration, and examples thereof include oral administration, tube administration, and enteral administration. Oral administration is preferred from the viewpoint of convenience and safety.
- the dosage form is not particularly limited, and can be appropriately selected depending on the administration route.
- Oral preparations can be made into various known dosage forms, such as granules, powders, tablets, pills, capsules, solutions, syrups, emulsions, suspensions, lozenges, and the like. can do.
- enteric preparation it can be more efficiently transported to the intestine without receiving the effect of gastric acid.
- parenteral administration include administration in the form of injections.
- the probiotic of the present invention a culture thereof or a processed product thereof can be locally administered to an area to be treated. For example, it can be administered by local injection during surgery or by use of a catheter.
- Carriers that can be used in the pharmaceutical composition of the present invention include surfactants, excipients, coloring agents, flavoring agents, preservatives, stabilizers, buffers, suspending agents, isotonic agents, binders, and disintegrants.
- Lubricants, fluidity promoters, flavoring agents and the like are listed as pharmaceutically acceptable carriers, and other commonly used carriers can be used as appropriate.
- the present invention has been completed based on the new finding that probiotics capable of activating AhR exist, and thus a method for screening probiotics having the ability to activate AhR and the method Also encompassed by the present invention are methods of activating AhR, and methods for preventing and / or treating inflammatory diseases comprising administering to a subject a screened probiotic.
- the inflammatory disease may be systemic or local, and the inflammatory site may be any of skin, mucous membrane, digestive organ, respiratory organ, liver, blood vessel, uterus, and the like.
- a inflammatory bowel disease can be mentioned as a suitable example of an inflammatory disease, It is not limited to this example.
- AhR when activated, AhR moves into the nucleus and binds to a foreign body response element (XRE, dioxin response element: also called DioxinoxResponsive Element, DRE) on DNA, for example, cytochrome P450 enzyme ( causes downstream gene expression, such as CYP1A1). Therefore, by stimulating AhR-expressing cells having an expression unit containing at least one XRE sequence and a reporter gene region downstream thereof with a candidate probiotic and / or culture supernatant thereof, and observing the expression of the reporter gene, It can be tested whether probiotics have the ability to activate AhR.
- XRE dioxin response element
- DRE DioxinoxResponsive Element
- any cell can be used as the AhR-expressing cell used in the present invention as long as it can be used in the bioassay.
- HeXS34 cells, Caco-2 cells and the like are preferable.
- the expression unit containing the XRE and the downstream reporter gene of such AhR-expressing cells may be endogenous or introduced from the outside by transformation or the like. From the viewpoint of specializing in assays, low detection noise, and the like, it preferably has an expression unit introduced from the outside.
- any gene may be used as long as it can quantitatively measure the expression level of mRNA and / or protein that is a transcription product of the gene.
- AhR activation ability can be detected by quantitatively detecting the expression level of the above-mentioned CYP1A1 using, for example, quantitative real-time PCR.
- a test system using Caco2 cells described in Experimental Example 3 described later there can be mentioned a test system using Caco2 cells described in Experimental Example 3 described later.
- any reporter gene known to those skilled in the art for bioassay can be used.
- secretory alkaline Phosphatase SEAP
- secretory luciferase GFP
- GFP green fluorescent protein
- the plasmid used to introduce the expression unit into the cell from the outside is a plasmid containing at least one XRE sequence and a reporter gene downstream thereof, this is called a foreign body responsive plasmid.
- the reporter gene of the foreign substance responsive plasmid is SEAP
- the foreign substance responsive plasmid can be represented as pXRE-SEAP.
- Preparation of foreign-responsible plasmid and introduction into cells can be performed according to, for example, WO2005 / 113767, WO2007 / 004361, Kasai et al. (Kasai et al., Toxicol Appl Pharmacol. 2006; 211 (1): 11-19). It can be carried out.
- AhR-activating ability is measured by stimulating AhR-expressing cells with candidate probiotics and / or culture supernatants thereof, and quantifying the expression level of a reporter gene present downstream of the XRE sequence. can do.
- a high reporter gene expression level indicates a strong AhR activation ability. Therefore, as a screening method, after coculturing candidate probiotics and AhR-expressing cells, the expression level of the reporter gene is measured, and compared with the expression level of the reporter gene in the negative control measured in the same manner. If it is high, it can be determined that it has AhR activation ability.
- “stimulating” an AhR-expressing cell typically means incubating the AhR-expressing cell for a certain period of time in the presence of a candidate probiotic and / or its culture supernatant. Therefore, when the candidate probiotic is a living bacterium, a mode in which AhR-expressing cells and the candidate probiotic are co-cultured, or in the presence of dead cells, secretions, crushed material and / or culture supernatant for a certain period of time Including an embodiment of incubating. The incubation time may be appropriately selected depending on the candidate probiotic, the cell to be tested, the expression level of AhR, the type of reporter gene, and the like.
- Example 1 Screening of lactic acid bacteria having AhR activation ability (1) Preparation of HeXS34 cells Preparation of HeXS34 cells was performed according to a previous report (Kasai et al., Toxicol Appl Pharmacol. 2006; 211 (1): 11-19). Briefly, the foreign body responsive plasmid pXRE-SEAP in which the SEAP gene was introduced downstream of two copies of the XRE consensus sequence (tctcacgcaactccg) was transformed into Hepa-1c1c7 cells (murine hepatoma cell line, American Type Culture Collection (Manassas, VA, HeXS34 cells were prepared by stable transformation into USA)).
- SEAP assay SEAP was quantified by chemiluminescence method using Great EscAPe SEAP Chemiluminescence kit (Clontech) to the culture supernatant obtained in (2). The assay was performed three times, and the obtained luminescence intensity (LU) was defined as SEAP activity, and the average value was obtained.
- Example 2 By screening of SEAP activity inhibition example 1 by ⁇ NF, OLL1181 strain was selected as a candidate strain having AhR activation ability and MEP222701 strain was selected as a negative control not having AhR activation ability, and was subjected to further experiments.
- the suspension of the two kinds of lactic acid bacteria strains (5 ⁇ 10 9 cells / ml solution added at 5% v / v and 10% v / v, respectively) for 24 hours Stimulated and the culture supernatant was subjected to SEAP assay.
- FIG. A is a graph comparing the SEAP activity of OL1181 strain and MEP222701 strain, but OL1181 strain has a 5% v / v (2.5 ⁇ ) addition amount of lactic acid strain suspension compared to the untreated group. 10 8 cells / ml well) and 10% v / v (5 ⁇ 10 8 cells / ml well) both significantly increased the SEAP activity.
- B is a graph comparing the amount of lactic acid strain suspension added to 10% v / v (5 ⁇ 10 8 cells / ml well) and not preincubated with ⁇ NF, but preincubated with ⁇ NF.
- the one significantly inhibited the increase in SEAP activity by stimulation with the OLL1181 strain. From this result, it was considered that the increase in SEAP activity by stimulation with OLL1181 strain was due to activation of the XRE sequence by AhR activation.
- Example 3 Verification of AhR activation ability using Caco2 cells
- AcoR2 activation cells were used to verify AhR activation ability.
- Human Caco2 cells were cultured in DMEM medium (Invitrogen / Gibco, arlsbad, Calif.) Supplemented with 10% FBS and antibiotics, and some were preincubated with 5 ⁇ M ⁇ NF for 30 minutes, but not preincubated Both were stimulated with 10% v / v heat-killed OLL1181 strain suspension for 4 hours.
- Quantitative real-time PCR Caco2 cells obtained in (1) were subjected to quantitative real-time PCR. Quantitative real-time PCR was performed based on instruction manual using ABI 7300 real-time PCR system (Applied Biosystems, Foster City, CA). The primers and probes used for human CYP1A1 (Assay ID: Hs02382618_s1) and glyceraldehyde-3-phosphate dehydrogenase (GAPDH) (Assay ID: Hs99999905_m1) (Applied Biosystems) were used. The expression level of the CYP1A1 gene relative to the expression level of the GAPDH gene was calculated and expressed as the relative expression level of the CYP1A1 gene.
- Example 4 In vivo AhR-activated C57BL / 6 mice aged 4-6 weeks (female, body weight 14-18 g, purchased from Japan SLC) were each 200 ⁇ l of heat-killed OLL1181 strain suspension and heat-killed MEP222701 strain suspension. Suspension (5 ⁇ 10 9 cells / ml) and PBS were orally administered by a stomach tube. The dose of each strain corresponds to 1 ⁇ 10 9 cells / body. 4. 4 hours after administration, the large intestine was excised.
- the relative expression level of CYP1A1 was quantified by quantitative real-time PCR using primers and probes for mouse CYP1A1 (Assay ID: Mm00487218_m1) and GAPDH (Assay ID: Mm99999915_g1).
- Example 5 Induction of COX2 expression and production of prostaglandin E2 in vitro and in vivo (1) Verification of COX-2 expression AhR activation by OLL1181 strain stimulation induces COX-2 expression, thereby arachidonic acid As a primer and probe for quantitative real-time PCR, human and mouse COX-2 (human assay ID: Hs01573469_m1, mouse assay ID: Mm01307334_g1) and GAPDH The expression of COX-2 in vitro and in vivo was confirmed by the same method as in Example 3 and Example 4 except that the product for use was used. The expression level of the COX-2 gene relative to the expression level of the GAPDH gene was calculated, and the relative expression level of the COX-2 gene was shown.
- PGE2 Prostaglandin E2
- MEP222761 that showed high AhR activity in the screening of Example 1 was used as a stimulating lactic acid bacterium, and human Caco2 cells were stimulated in the same manner as in Example 3 (1) except that the stimulation time was 24 hours. Then, the amount of PGE2 secreted into the culture supernatant was quantified using a PGE2 Competitive ELISA kit (Thermo Scientific inc., Watham, MA) according to the instruction manual.
- FIG. A represents the relative expression level of COX-2 in human Caco2 cells in vitro
- B represents the relative expression level of COX-2 in vivo in mouse large intestine
- C represents the amount of PGE2 production in human Caco2 cells. It was confirmed that the expression of COX-2 was significantly increased in both human in vitro and mouse in vivo by stimulation with the OLL1181 strain as compared with the negative control. Furthermore, in human Caco2 cells, production of PGE2 was confirmed by stimulation with OLL1181 strain. Since such PGE2 production was inhibited by ⁇ NF, it was confirmed that it was PGE2 production derived from AhR activation.
- Example 6 AhR activation by OL1181 strain is a distilled distillation for 7 days in C57BL / 6 mice 4-6 weeks old (female, body weight 14-18 g, purchased from Japan SLC) to induce enteritis to alleviate DSS-induced enteritis 3% dextran sulfate sodium (DSS, molecular weight 5000, purchased from Wako Pure Chemical Industries, Ltd.) dissolved in water was freely ingested every day, and then distilled water without DSS was ingested freely for 3 days.
- DSS dextran sulfate sodium
- the dose of each strain corresponds to 1 ⁇ 10 9 cells / body.
- 200 ⁇ l of PBS was orally administered daily for 7 days instead of the bacterial solution.
- 200 ⁇ l of PBS was orally administered daily for 7 days in the non-colitis induced group to which DSS was not administered.
- TNF- ⁇ and MPO were quantified using primers and probes for mouse TNF- ⁇ (Assay ID: Mm00443258_m1) and mouse myeloperoxidase (MPO) (Assay ID: Mm00447886_m1). Real-time PCR.
- FIG. A is a graph showing the survival rate of each group up to the 11th day.
- the survival rate on the 11th day was about 20% in the control group (DSS) administered with PBS and the MEP222701 strain administered group (MEP222701), but the MEP2222761 strain administered group (MEP222761) had a survival rate of about 40% (data not shown), and the OLL1181 strain administration group (OLL1181) had a survival rate of about 80%.
- B represents changes in body weight of the DSS colitis-induced group (DSS), the DSS colitis-non-induced group (PBS), and the DSS colitis-induced + OLL1181 strain administration group (OLL1181).
- the DSS colitis-induced group (DSS) tended to lose weight, but the OLL1181 strain-administered group increased the average body weight from the 8th day compared to the colitis-induced group (DSS), starting on the 10th day. Some weight gain was confirmed.
- C represents the length of the large intestine of the DSS colitis induction group (DSS), the DSS colitis non-induction group (PBS), and the DSS colitis induction + OLL1181 strain administration group (OLL1181) on the 11th day. Compared with the DSS colitis induction group (DSS), the colon of the OLL1181 strain administration group was significantly longer.
- D represents the expression levels of TNF- ⁇ and MPO in the large intestine of the DSS colitis-induced group (DSS), DSS colitis-non-induced group (PBS), and DSS colitis-induced + OLL1181 strain administration group (DSS + OLL1181) on the 11th day.
- DSS DSS colitis-induced group
- PBS DSS colitis-non-induced group
- DSS colitis-induced + OLL1181 strain administration group DSS colitis-induced + OLL1181 strain administration group
- Example 7 Manufacture fermented dairy products (plain yogurt) Mix milk, dairy products, and water so that the final product is 9.5% non-fat milk solids and 3.0% milk fat. Prepared. Next, the prepared yogurt base mix was homogenized and then heat sterilized at 95 ° C. for 5 minutes, and then cooled to about 40 ° C. The above-mentioned yogurt base mix was inoculated with a mixed starter of Lactobacillus bulgaricus OLL2038 and Streptococcus thermophilus OLL1131 isolated from "Meiji Bulgaria Yogurt", and fermented to produce yogurt (Control A). In addition, yogurt was produced in the same manner as the control product except that Lactobacillus bulgaricus OLL1181 strain was used instead of the mixed starter Lactobacillus bulgaricus OLL2038 (Invention A).
- yogurt (invention product A) produced by the OLL1181 strain has a preferable flavor and physical properties equal to or higher than those of the control product yogurt (control product A). Was shown to have.
- Example 8 Manufacture of fermented dairy products (drink yogurt) Base for drink yogurt by mixing milk, dairy products and water so that the final product has a non-fat milk solid content of 8.0% and a milk fat content of 0.5% After preparing and homogenizing the mix, it was sterilized by heating at 95 ° C. for 10 minutes and then cooled to about 40 ° C.
- This drink yogurt base mix was inoculated with the same yogurt starter as in Example 8 (mixed starter of Lactobacillus bulgaricus OLL2038 and Streptococcus thermophilus OLL1131 isolated from “Meiji Bulgaria yogurt”) And fermented milk for drink yogurt was prepared. The obtained fermented milk for drink yogurt was homogenized to obtain liquid fermented milk for drink yogurt.
- the drink yogurt liquid fermented milk and the sterilized sugar liquid were mixed at a mass ratio of 6: 4 to produce a drink yogurt (control product B).
- a drink yogurt was produced in the same manner as the control product except that Lactobacillus bulgaricus OLL1181 strain was used instead of the mixed starter Lactobacillus bulgaricus OLL2038 (Invention B).
- the drink yogurt (Invention B) obtained by the OLL1181 strain is preferable in comparison with the control drink yogurt (Control B). Was shown to have.
- the pH was measured at 5 ° C. using a glass electrode pH meter (HM30-R, manufactured by DKK-TOA).
- the lactic acid acidity was calculated by titrating with 0.1N NaOH and using phenolphthalein as an indicator.
- the card tension of yogurt is measured by using a card meter MAX ME500 (Asuka Instruments), applying a constant speed load with a weight of 100 g to the sample through a spring, measuring the strain caused by the deformation using a load cell, until breaking.
- the elasticity of was defined as hardness (g).
- the viscosity is 5 ° C using model RB200 and controller RC-100 (Toki Sangyo).
- the measurement was performed at 60 rpm for 30 seconds using one rotor. Flavor was judged by three expert panelists in three stages: good, appropriate, and poor.
- the probiotics of the present invention it is possible to alleviate inflammatory gastrointestinal diseases by acting on the intestinal environment, inflammatory digestion that has been refractory until now and has only been symptomatically treated with drugs. Tube disease can be fundamentally treated. Furthermore, since the probiotic of the present invention does not have biotoxicity, it can be easily and effectively ingested by containing it in a pharmaceutical composition or food composition.
Landscapes
- Life Sciences & Earth Sciences (AREA)
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Engineering & Computer Science (AREA)
- Microbiology (AREA)
- Organic Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Zoology (AREA)
- Wood Science & Technology (AREA)
- Mycology (AREA)
- Medicinal Chemistry (AREA)
- Genetics & Genomics (AREA)
- Biotechnology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Molecular Biology (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Biochemistry (AREA)
- Epidemiology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- General Engineering & Computer Science (AREA)
- Polymers & Plastics (AREA)
- Biomedical Technology (AREA)
- Food Science & Technology (AREA)
- Analytical Chemistry (AREA)
- Biophysics (AREA)
- Physics & Mathematics (AREA)
- Immunology (AREA)
- Tropical Medicine & Parasitology (AREA)
- Virology (AREA)
- Nutrition Science (AREA)
- Animal Husbandry (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Physiology (AREA)
- Pain & Pain Management (AREA)
- Rheumatology (AREA)
Abstract
Description
(1)芳香族炭化水素レセプター(AhR)活性化能を有する、プロバイオティクス。
(2)プロバイオティクスが、乳酸菌、ビフィズス菌およびプロピオン酸菌からなる群から選択される、(1)に記載のプロバイオティクス。
(3)プロバイオティクスが、乳酸菌である、(1)または(2)に記載のプロバイオティクス。
(4)Lactobacillus delbrueckii subsp. bulgaricus OLL1181菌株(受託番号:FERM BP-11269)。
(6)AhR活性化能を有するプロバイオティクスが、乳酸菌、ビフィズス菌およびプロピオン酸菌からなる群から選択される、(5)に記載の抗炎症剤。
(7)AhR活性化能を有するプロバイオティクスが、乳酸菌である、(5)または(6)に記載の抗炎症剤。
(8)AhR活性化能を有するプロバイオティクスが、Lactobacillus delbrueckii subsp. bulgaricus OLL1181菌株である、(5)~(7)のいずれかに記載の抗炎症剤。
(10)経口摂取用組成物が、飲料品組成物、食品組成物、飼料組成物および医薬組成物からなる群から選択される、(9)に記載の経口摂取用組成物。
本発明において、「AhR活性化能」とは、AhR活性化によって開始されるシグナル伝達経路を活性化することができる能力のことをいい、活性化するメカニズムは何であってもよい。したがって、必ずしも菌体そのものがAhRのリガンドである必要はなく、例えば菌が産生する分泌物質がAhR活性化能を有していてもよいし、死菌体またはその破砕物などによってAhRが活性化されてもよい。したがって、本発明において「微生物」、「細菌」という場合または特定の菌についていう場合、生菌そのものだけでなく、死菌体またはその破砕物、該菌の培養物または分泌物も含まれる。しかし、好ましくは生菌、死菌体またはその破砕物などの菌体そのものであり、消化管内で細菌叢を形成することができるという観点から、より好ましくは生菌である。
(a)形態的性質
桿菌
(b)培養的性質
培地名:Lactobacilli MRS Broth (Difco, Ref. No. 288130)
pH:無調整
培養温度:37℃
培養時間:18時間
(1)形状:円形
(2)直径:1~2mm
(3)色調:白色
(4)隆起状態:半球状
(5)周縁:全縁
(6)表面形状:スムーズ
(7)透明度:不透明
(8)粘稠度:バター様
(c)生理学的性質
(1)グラム染色性:陽性
(2)乳酸発酵形式:ホモ乳酸発酵
(3)酸素要求性:通性嫌気
(4)発育温度:15℃+、45℃-
しかしながら、本発明のプロバイオティクス、抗炎症剤、または経口摂取用組成物の摂取量は、上記に挙げた値に限定されるものではない。
しかしながら、本発明の抗炎症剤または経口摂取用組成物に含まれるプロバイオティクスの含量は、上記に挙げた値に限定されるものではない。
タンパク質としては、例えば全脂粉乳、脱脂粉乳、部分脱脂粉乳、カゼイン、ホエイ粉、ホエイタンパク質、ホエイタンパク質濃縮物、ホエイタンパク質分離物、α-カゼイン、β-カゼイン、κ-カゼイン、β-ラクトグロブリン、α-ラクトアルブミン、ラクトフェリン、大豆タンパク質、鶏卵タンパク質、肉タンパク質などの動植物性タンパク質、これら加水分解物;バター、乳性ミネラル、クリーム、ホエイ、非タンパク態窒素、シアル酸、リン脂質、乳糖などの各種乳由来成分などが挙げられる。
ビタミン類としては、例えば、ビタミンA、カロチン類、ビタミンB群、ビタミンC、ビタミンD群、ビタミンE、ビタミンK群、ビタミンP、ビタミンQ、ナイアシン、ニコチン酸、パントテン酸、ビオチン、イノシトール、コリン、葉酸などが挙げられ、ミネラル類としては、例えば、カルシウム、カリウム、マグネシウム、ナトリウム、銅、鉄、マンガン、亜鉛、セレンなどが挙げられる。
非経口的な投与としては、注射剤などの形での投与を挙げることができる。また、本発明のプロバイオティクス、その培養物またはその加工物を、処置を施したい領域に局所的に投与することもできる。例えば、手術中の局所注入、カテーテルの使用により投与することも可能である。
本発明において、前記発現ユニットを外部から細胞に導入するために使用するプラスミドが、少なくとも1のXRE配列およびその下流のレポーター遺伝子を含むプラスミドである場合、これを異物応答性プラスミドという。また、前記異物応答性プラスミドのレポーター遺伝子がSEAPである場合、異物応答性プラスミドをpXRE-SEAPと表すことができる。異物応答性プラスミドの作製および細胞への導入は、例えばWO2005/113767、WO2007/004361、Kasaiらの論文(Kasai et al., Toxicol Appl Pharmacol. 2006; 211(1):11-19)に準じて行うことができる。
(1)HeXS34細胞の調製
HeXS34細胞の調製は、既報(Kasai et al., Toxicol Appl Pharmacol. 2006; 211(1):11-19)に従って行った。簡潔には、2コピーのXREコンセンサス配列(tctcacgcaactccg)の下流にSEAP遺伝子を導入した異物応答性プラスミドpXRE-SEAPを、Hepa-1c1c7細胞(ネズミヘパトーマ細胞株、American Type Culture Collection (Manassas,VA, USA))に安定的に形質転換することにより、HeXS34細胞を調製した。
MEMα培地(Invitrogen, Carlsbad, CA)に10%のウシ胎児血清(FBS)を添加した培地で維持した、(1)で調製したHeXS34細胞を、96ウェルプレートに、ウェル毎に5000個/90μlで播種し、凍結乾燥した熱殺菌済み乳酸菌株10μl(5×109個/ml)の存在下および非存在下で24時間培養した。ポジティブコントロールとして、50pMの2,3,7,8-テトラクロロジベンゾダイオキシン(TCDD)を用いた。また、ネガティブコントロールとして、乳酸菌またはTCDDを添加しないウェルを設けた。培養上清を、続くSEAPアッセイに供した。
(2)で得られた培養上清にGreat EscAPe SEAP Chemiluminescence kit(Clontech)を用いて、化学発光法によりSEAPを定量した。アッセイは3度行い、得られた発光強度(LU)をSEAP活性とし、その平均値を求めた。
なお、菌株名にMEPと記載された菌株は株式会社明治保有菌株である。また、菌種名は下記の表の通りである。
例1のスクリーニングによって、AhR活性化能を有する候補菌株としてOLL1181菌株、AhR活性化能を有さないネガティブコントロールとしてMEP222701菌株を選択し、さらなる実験に供した。例1と同様に、熱殺菌済みの前記2種の乳酸菌株懸濁液(5×109個/ml溶液をそれぞれ5%v/vおよび10%v/vで添加したのもの)で24時間刺激し、培養上清をSEAPアッセイに供した。またXRE領域の活性化にAhRが作用していることを明確に示すため、乳酸菌による刺激の前に、10μMのα-ナフトフラボン(αNF、AhRのアンタゴニスト)で30分間プレインキュベートしたHeXS34細胞とプレインキュベートしなかったHexS34細胞を用いて、それぞれ10%v/vの熱殺菌済みOLL1181菌株懸濁液で24時間刺激後、培養上清を例1.(3)と同様にSEAPアッセイに供した。
(1)Caco2細胞の刺激
ヒト結腸癌由来の細胞であるCaco2細胞を用いて、AhR活性化能の検証を行った。ヒトCaco2細胞を、10%FBSおよび抗生物質を添加したDMEM培地(Invitrogen/Gibco, arlsbad, CA)で培養し、一部を5μMのαNFで30分間プレインキュベートしたのち、プレインキュベートしたものとしていないもの両方について、10%v/vの熱殺菌済みOLL1181菌株懸濁液で4時間刺激した。
(1)で得られたCaco2細胞を定量的リアルタイムPCRに供した。定量的リアルタイムPCRは、ABI 7300 real-time PCRシステム(Applied Biosystems, Foster City, CA)を用いて、取扱説明書に基づいて行った。プライマーおよびプローブは、ヒトのCYP1A1用(Assay ID:Hs02382618_s1)およびグリセルアルデヒド-3-リン酸脱水素酵素(GAPDH)用(Assay ID:Hs99999905_m1)のもの(Applied Biosystems)を用いた。GAPDH遺伝子の発現量に対するCYP1A1遺伝子の発現量を計算し、CYP1A1遺伝子の相対発現量として示した。
4~6週齢のC57BL/6マウス(雌、体重14~18g、日本SLC社から購入)に、それぞれ200μlの熱殺菌済みOLL1181菌株懸濁液、熱殺菌済みMEP222701菌株懸濁液(5×109個/ml)およびPBSを胃ゾンデにより経口投与した。各菌株の投与用量は、1×109個/bodyに相当する。投与4時間後に大腸を切除し、例3.(2)と同様に、マウスのCYP1A1用(Assay ID:Mm00487218_m1)およびGAPDH用(Assay ID:Mm99999915_g1)プライマーおよびプローブを用いて、定量的リアルタイムPCRでCYP1A1の相対発現量を定量した。
(1)COX-2の発現誘導検証
OLL1181菌株刺激によるAhR活性化によって、COX-2の発現が誘導され、それによってアラキドン酸からプロスタグランジンE2の産生が亢進することを検証するため、定量的リアルタイムPCRのプライマーおよびプローブとして、ヒトおよびマウスのCOX-2(ヒト用Assay ID:Hs01573469_m1、マウス用Assay ID:Mm01307334_g1)およびGAPDH用のものを用いた以外は例3および例4と同様の方法で、COX-2のin vitroおよびin vivoでの発現を確認した。GAPDH遺伝子の発現量に対するCOX-2遺伝子の発現量を計算し、COX-2遺伝子の相対発現量をとして示した。
刺激用の乳酸菌として、OLL1181およびMEP222701に加えて、例1のスクリーニングで高いAhR活性を示したMEP222761も用い、刺激時間を24時間とした以外は例3(1)と同様にヒトCaco2細胞を刺激し、培養上清中に分泌されたPGE2の量を、PGE2 Competitive ELISA kit(Thermo Scientific inc., Watham, MA)を用いて、取扱説明書にしたがって定量した。
腸炎の誘導のため、4~6週齢のC57BL/6マウス(雌、体重14~18g、日本SLC社から購入)に7日間、飲用蒸留水に溶解した3%デキストラン硫酸ナトリウム(DSS、分子量5000、和光純薬工業株式会社より購入)を毎日自由摂取させ、その後DSSの入っていない蒸留水を3日間自由摂取させた。菌株による緩和効果を検証するため、熱殺菌したOLL1181菌株、MEP222701菌株およびMEP222761菌株を7日間毎日200μl(5×109個/ml)、胃ゾンデにより経口投与した。各菌株の投与用量は、1×109個/bodyに相当する。コントロールとして、菌液に代えてPBSを200μl、7日間毎日経口投与した。また、DSSを投与しない大腸炎非誘発群にもPBSを200μl、7日間毎日経口投与した。実験は各群n=10~12で行い、DSSの投与開始から11日目に大腸を切除し、大腸の長さを計測し、例3.(2)と同様に、マウスTNF-α用(Assay ID:Mm00443258_m1)およびマウスミエロペルオキシダーゼ(MPO)(Assay ID:Mm00447886_m1)用のプライマーおよびプローブを用いて、TNF-αおよびMPOの発現量を定量的リアルタイムPCRで定量した。
Cは11日目におけるDSS大腸炎誘発群(DSS)、DSS大腸炎非誘発群(PBS)およびDSS大腸炎誘発+OLL1181菌株投与群(OLL1181)の大腸の長さを表す。DSS大腸炎誘発群(DSS)と比較して、OLL1181菌株投与群は有意に大腸が長かった。
牛乳と乳製品と水を最終製品の無脂乳固形分が9.5%、乳脂肪分が3.0%となるように混合して、ヨーグルトベースミックスを調製した。次に、調製したヨーグルトベースミックスを均質化後、95℃、5分間加熱殺菌し、その後、約40℃まで冷却した。
前述のヨーグルトベースミックスに、「明治ブルガリアヨーグルト」より単離したラクトバチルス・ブルガリカス(Lactobacillus bulgaricus OLL2038)とストレプトコッカス・サーモフィルス(Streptococcus thermophilus OLL1131)の混合スターターを接種して、発酵させヨーグルトを製造した(対照品A)。また、混合スターターのLactobacillus bulgaricus OLL2038の代わりにLactobacillus bulgaricus OLL1181菌株を使用すること以外は、対照品と同様の方法でヨーグルトを製造した(発明品A)。
牛乳と乳製品と水を最終製品の無脂乳固形分が8.0%、乳脂肪分が0.5%となるように混合して、ドリンクヨーグルト用ベースミックスを調製し、均質化後、これを95℃、10分間で加熱殺菌した後に約40℃に冷却した。このドリンクヨーグルト用ベースミックスに例8と同様のヨーグルトスターター(「明治ブルガリアヨーグルト」より単離したラクトバチルス・ブルガリカス(Lactobacillus bulgaricus OLL2038)とストレプトコッカス・サーモフィルス(Streptococcus thermophilus OLL1131)の混合スターター)を接種し、発酵させ、ドリンクヨーグルト用発酵乳を調製した。この得られたドリンクヨーグルト用発酵乳について、均質化して、ドリンクヨーグルト用液状発酵乳を得た。このドリンクヨーグルト用液状発酵乳と殺菌した糖液を質量比で6:4にて混合して、ドリンクヨーグルトを製造した(対照品B)。また、混合スターターのLactobacillus bulgaricus OLL2038の代わりにLactobacillus bulgaricus OLL1181菌株を使用すること以外は、対照品と同様の方法でドリンクヨーグルトを製造した(発明品B)。
pHは、5℃にてガラス電極のpHメーター(HM30-R,DKK-TOA製)を用いて測定した。
乳酸酸度は、0.1規定NaOHを用い、フェノールフタレインを指示薬として滴定し、算出した。
ヨーグルトのカードテンションは、カードメーターMAX ME500(飛鳥機器)を使用し、試料にスプリングを介して100gの重りによる定速荷重を加え、変形により生ずる歪みをロードセルを用いて計測し、破断に至るまでの弾力性を硬度(g)とした。
粘度は品温5℃にてモデルRB200、コントローラーRC-100(東機産業)を使用し、No.1ローターを用い60rpm、30秒間の条件で測定した。
風味は、5名の専門パネラーにより、良好、適、不良の3段階で判定した。
Claims (11)
- 芳香族炭化水素レセプター(AhR)活性化能を有する、プロバイオティクス。
- プロバイオティクスが、乳酸菌、ビフィズス菌およびプロピオン酸菌からなる群から選択される、請求項1に記載のプロバイオティクス。
- プロバイオティクスが、乳酸菌である、請求項1または2に記載のプロバイオティクス。
- Lactobacillus delbrueckii subsp. bulgaricus OLL1181菌株(受託番号:FERM BP-11269)。
- AhR活性化能を有するプロバイオティクスを含む、抗炎症剤。
- AhR活性化能を有するプロバイオティクスが、乳酸菌、ビフィズス菌およびプロピオン酸菌からなる群から選択される、請求項5に記載の抗炎症剤。
- プロバイオティクスが、乳酸菌である、請求項5または6に記載の抗炎症剤。
- AhR活性化能を有するプロバイオティクスが、Lactobacillus delbrueckii subsp. bulgaricus OLL1181菌株である、請求項5~7のいずれか一項に記載の抗炎症剤。
- 請求項5~8のいずれか一項に記載の抗炎症剤を含む、経口摂取用組成物。
- 経口摂取用組成物が、飲料品組成物、食品組成物、飼料組成物および医薬組成物からなる群から選択される、請求項9に記載の経口摂取用組成物。
- 異物応答配列(XRE)およびその下流のレポーター遺伝子領域を含む発現ユニットを有するAhR発現細胞を、候補プロバイオティクスおよび/またはその培養上清で刺激する工程を含む、AhR活性化能を有するプロバイオティクスをスクリーニングする方法。
Priority Applications (7)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
EP11823625.6A EP2615163B1 (en) | 2010-09-09 | 2011-09-08 | Composition comprising probiotics having aryl hydrocarbon receptor activating potency for use as anti-inflammatory agents |
US13/821,284 US9095604B2 (en) | 2010-09-09 | 2011-09-08 | Composition for preventing inflammations |
JP2012533018A JP5919193B2 (ja) | 2010-09-09 | 2011-09-08 | 炎症を抑制する組成物 |
CA2810698A CA2810698A1 (en) | 2010-09-09 | 2011-09-08 | Aryl hydrocarbon receptor-activating probiotics for preventing inflammation |
SG2013016605A SG188425A1 (en) | 2010-09-09 | 2011-09-08 | Composition for preventing inflammations |
CN201180041925.5A CN103261399B (zh) | 2010-09-09 | 2011-09-08 | 抑制炎症的组合物 |
HK13112117.8A HK1184816A1 (en) | 2010-09-09 | 2013-10-28 | Composition for preventing inflammations |
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
JP2010-202383 | 2010-09-09 | ||
JP2010202383 | 2010-09-09 |
Publications (1)
Publication Number | Publication Date |
---|---|
WO2012033151A1 true WO2012033151A1 (ja) | 2012-03-15 |
Family
ID=45810747
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/JP2011/070436 WO2012033151A1 (ja) | 2010-09-09 | 2011-09-08 | 炎症を抑制する組成物 |
Country Status (9)
Country | Link |
---|---|
US (1) | US9095604B2 (ja) |
EP (1) | EP2615163B1 (ja) |
JP (1) | JP5919193B2 (ja) |
CN (1) | CN103261399B (ja) |
CA (1) | CA2810698A1 (ja) |
HK (1) | HK1184816A1 (ja) |
SG (1) | SG188425A1 (ja) |
TW (1) | TWI572354B (ja) |
WO (1) | WO2012033151A1 (ja) |
Cited By (7)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2016103699A1 (ja) * | 2014-12-26 | 2016-06-30 | 株式会社明治 | 有機酸の産生促進剤、並びに炎症性腸疾患の予防及び/又は改善剤 |
JP2016190804A (ja) * | 2015-03-31 | 2016-11-10 | 雪印メグミルク株式会社 | Iald産生促進剤 |
JP2017202990A (ja) * | 2016-05-10 | 2017-11-16 | 丸善製薬株式会社 | 化粧料および飲食品組成物 |
JP2018061473A (ja) * | 2016-10-13 | 2018-04-19 | 株式会社明治 | 高いAhR活性化能を有する乳酸菌 |
JP2019502737A (ja) * | 2016-01-19 | 2019-01-31 | シムライズ アーゲー | 口腔内の抗炎症剤として用いるためのプロバイオティクス |
US11198848B2 (en) | 2016-01-19 | 2021-12-14 | Symrise Ag | Probiotics for altering the composition of oral biofilms |
US11338001B2 (en) | 2017-01-18 | 2022-05-24 | Symrise Ag | Probiotics for aggregation with disease-associated species in the oral cavity |
Families Citing this family (15)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
ES2436251B1 (es) | 2012-05-25 | 2014-10-08 | Consejo Superior De Investigaciones Científicas (Csic) | Bacteroides cect 7771 y su uso en la prevención y tratamiento de sobrepeso, obesidad y alteraciones metabólicas e inmunológicas. |
KR101393825B1 (ko) * | 2012-07-03 | 2014-05-12 | 경희대학교 산학협력단 | 백부근 추출물을 포함하는 염증성 장질환의 예방 또는 치료효과를 갖는 약학 조성물 |
KR101379111B1 (ko) * | 2012-07-03 | 2014-03-31 | 경희대학교 산학협력단 | 염증성 장질환의 예방 또는 치료효과를 갖는 약학 조성물 |
US20160206666A1 (en) | 2014-12-22 | 2016-07-21 | Synlogic, Inc. | Bacteria engineered to treat diseases that benefit from reduced gut inflammation and/or tighten gut mucosal barrier |
US11291693B2 (en) | 2015-06-25 | 2022-04-05 | Synlogic Operating Company, Inc. | Bacteria engineered to treat metabolic diseases |
US10736927B2 (en) | 2015-08-21 | 2020-08-11 | Inserm (Institute National De La Santé Et De La Recherche Medicale) | Pharmaceutical compositions for preventing or treating inflammatory bowel diseases |
EP3167892A1 (en) | 2015-11-10 | 2017-05-17 | INSERM (Institut National de la Santé et de la Recherche Médicale) | Methods and pharmaceutical compositions for preventing or treating imflammatory bowel diseases |
US11685925B2 (en) * | 2015-10-30 | 2023-06-27 | Synlogic Operating Company, Inc. | Bacteria engineered to treat diseases that benefit from reduced gut inflammation and/or tightened gut mucosal barrier |
EP3402497A1 (en) * | 2016-01-11 | 2018-11-21 | Synlogic Operating Company, Inc. | Bacteria engineered to treat metabolic diseases |
US11596657B2 (en) | 2016-10-04 | 2023-03-07 | Institut National De La Recherche Agronomique | Use of AhR agonist for the preventive or curative treatment of metabolic syndrome and the associated disorders |
CA3088630A1 (en) | 2017-12-15 | 2019-06-20 | Solarea Bio, Inc. | Microbial compositions and methods for treating type 2 diabetes, obesity, and metabolic syndrome |
US11980647B2 (en) | 2018-09-05 | 2024-05-14 | Solarea Bio, Inc. | Methods and compositions for treating musculoskeletal diseases, treating inflammation, and managing symptoms of menopause |
EP3846830A4 (en) | 2018-09-05 | 2022-07-06 | Solarea Bio, Inc. | METHODS AND COMPOSITIONS FOR THE TREATMENT OF MUSCULOSKELETAL DISEASES |
WO2023092150A1 (en) | 2021-11-22 | 2023-05-25 | Solarea Bio, Inc. | Methods and compositions for treating musculoskeletal diseases, treating inflammation, and managing symptoms of menopause |
US20230190834A1 (en) | 2021-12-21 | 2023-06-22 | Solarea Bio, Inc. | Immunomodulatory compositions comprising microbial entities |
Citations (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2005113767A1 (ja) | 2004-05-24 | 2005-12-01 | Yamanashi University | ダイオキシン類等応答性プラスミド、ダイオキシン類等測定用遺伝子導入細胞、並びにそれを用いたダイオキシン類等検出方法及びバイオセンサー |
WO2007004361A1 (ja) | 2005-07-01 | 2007-01-11 | Yamanashi University | 遺伝子導入非ヒト哺乳動物、およびこれを用いた環境中有害化学物質のモニタリング方法 |
Family Cites Families (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EP2034848B1 (en) * | 2006-06-16 | 2016-10-19 | DuPont Nutrition Biosciences ApS | Streptococcus thermophilus bacterium |
US7901925B2 (en) * | 2006-06-23 | 2011-03-08 | Bojrab Gregory G | Lactobacillus delbrueckii ssp. bulgaricus strain and compositions |
-
2011
- 2011-09-07 TW TW100132223A patent/TWI572354B/zh active
- 2011-09-08 EP EP11823625.6A patent/EP2615163B1/en active Active
- 2011-09-08 CN CN201180041925.5A patent/CN103261399B/zh active Active
- 2011-09-08 CA CA2810698A patent/CA2810698A1/en not_active Abandoned
- 2011-09-08 WO PCT/JP2011/070436 patent/WO2012033151A1/ja active Application Filing
- 2011-09-08 SG SG2013016605A patent/SG188425A1/en unknown
- 2011-09-08 JP JP2012533018A patent/JP5919193B2/ja active Active
- 2011-09-08 US US13/821,284 patent/US9095604B2/en active Active
-
2013
- 2013-10-28 HK HK13112117.8A patent/HK1184816A1/xx unknown
Patent Citations (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2005113767A1 (ja) | 2004-05-24 | 2005-12-01 | Yamanashi University | ダイオキシン類等応答性プラスミド、ダイオキシン類等測定用遺伝子導入細胞、並びにそれを用いたダイオキシン類等検出方法及びバイオセンサー |
WO2007004361A1 (ja) | 2005-07-01 | 2007-01-11 | Yamanashi University | 遺伝子導入非ヒト哺乳動物、およびこれを用いた環境中有害化学物質のモニタリング方法 |
Non-Patent Citations (12)
Title |
---|
HERIAS, M.V. ET AL.: "Probiotic effects of Lactobacillus casei on DSS-induced ulcerative colitis in mice.", INT. J. FOOD MICROBIOL., vol. 103, no. 2, 25 August 2005 (2005-08-25), pages 143 - 155, XP005002973 * |
KASAI ET AL., TOXICOL APPL PHARMACOL., vol. 211, no. 1, 2006, pages 11 - 19 |
KASAI, A. ET AL.: "DRESSA: biosensing of dioxin and dioxin-like chemicals using secreted alkaline phosphatase.", ANAL. BIOCHEM., vol. 335, no. 1, December 2004 (2004-12-01), pages 73 - 80, XP004616777 * |
KIMURA, A. ET AL., J EXP MED., vol. 206, no. 9, 31 August 2009 (2009-08-31), pages 2027 - 35 |
LEE, H-S. ET AL.: "Lactic acid bacteria inhibit Proinflammatory cytokine expression and bacterial glycosaminoglycan degradation activity in dextran sulfate sodium-induced colitic mice.", INT. IMMUNOPHARMACOL., vol. 8, no. 4, 5 February 2008 (2008-02-05), pages 574 - 580, XP022510890 * |
MARTEY, C.A. ET AL., AM J PHYSIOL LUNG CELL MOL PHYSIOL, vol. 289, 2005, pages L391 - L399 |
OSMAN, N. ET AL.: "Probiotics and Blueberry Attenuate the Severity of Dextran Sulfate Sodium (DSS)-Induced Colitis.", DIG. DIS. SCI., vol. 53, no. 9, 15 February 2008 (2008-02-15), pages 2464 - 2473, XP002501634 * |
See also references of EP2615163A4 |
STENSON, W.F., CURR OPIN GASTROENTEROL., vol. 23, no. 2, March 2007 (2007-03-01), pages 107 - 10 |
TAKAMURA, T. ET AL., IMMUNOLOGY AND CELL BIOLOGY, vol. 88, 2010, pages 685 - 689 |
TAKAMURA, T. ET AL.: "Activation of the aryl hydrocarbon receptor pathway may ameliorate dextran sodium sulfate-induced colitis in mice", IMMUNOL. CELL BIOL., vol. 88, 2010, pages 685 - 689 * |
TAKAMURA, T. ET AL.: "Lactobacillus bulgaricus OLL1181 activates the aryl hydrocarbon receptor pathway and inhibits colitis.", IMMUNOL. CELL BIOL., 15 February 2011 (2011-02-15), pages 1 - 6 * |
Cited By (11)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2016103699A1 (ja) * | 2014-12-26 | 2016-06-30 | 株式会社明治 | 有機酸の産生促進剤、並びに炎症性腸疾患の予防及び/又は改善剤 |
JPWO2016103699A1 (ja) * | 2014-12-26 | 2017-10-05 | 株式会社明治 | 有機酸の産生促進剤、並びに炎症性腸疾患の予防及び/又は改善剤 |
JP2016190804A (ja) * | 2015-03-31 | 2016-11-10 | 雪印メグミルク株式会社 | Iald産生促進剤 |
JP2019502737A (ja) * | 2016-01-19 | 2019-01-31 | シムライズ アーゲー | 口腔内の抗炎症剤として用いるためのプロバイオティクス |
US11198848B2 (en) | 2016-01-19 | 2021-12-14 | Symrise Ag | Probiotics for altering the composition of oral biofilms |
JP7065776B2 (ja) | 2016-01-19 | 2022-05-12 | シムライズ アーゲー | 口腔内の抗炎症剤として用いるためのプロバイオティクス |
JP2017202990A (ja) * | 2016-05-10 | 2017-11-16 | 丸善製薬株式会社 | 化粧料および飲食品組成物 |
JP2018061473A (ja) * | 2016-10-13 | 2018-04-19 | 株式会社明治 | 高いAhR活性化能を有する乳酸菌 |
JP2021101711A (ja) * | 2016-10-13 | 2021-07-15 | 株式会社明治 | 高いAhR活性化能を有する乳酸菌 |
JP7181954B2 (ja) | 2016-10-13 | 2022-12-01 | 株式会社明治 | 高いAhR活性化能を有する乳酸菌 |
US11338001B2 (en) | 2017-01-18 | 2022-05-24 | Symrise Ag | Probiotics for aggregation with disease-associated species in the oral cavity |
Also Published As
Publication number | Publication date |
---|---|
EP2615163B1 (en) | 2022-11-23 |
EP2615163A4 (en) | 2014-01-22 |
TW201215398A (en) | 2012-04-16 |
TWI572354B (zh) | 2017-03-01 |
HK1184816A1 (en) | 2014-01-30 |
CN103261399B (zh) | 2015-11-25 |
US9095604B2 (en) | 2015-08-04 |
CA2810698A1 (en) | 2012-03-15 |
JP5919193B2 (ja) | 2016-05-18 |
SG188425A1 (en) | 2013-04-30 |
US20130302844A1 (en) | 2013-11-14 |
CN103261399A (zh) | 2013-08-21 |
EP2615163A1 (en) | 2013-07-17 |
JPWO2012033151A1 (ja) | 2014-01-20 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
JP5919193B2 (ja) | 炎症を抑制する組成物 | |
JP5076029B2 (ja) | メタボリックシンドローム改善効果を有する乳酸菌 | |
JP6165185B2 (ja) | 乳酸菌又はその処理物を含む脂質代謝及び/又は糖代謝改善剤 | |
US9113641B2 (en) | Probiotic bacteria and regulation of fat storage | |
DK2478910T3 (en) | ANTI-ADIPOSITY AGENT, ANTI-ADIPOSITA NUTRITION OR DRINK, GLUCOSE TOLERANCE EFFECTIVE AGENT, AND NUTRITION OR DRINK FOR IMPROVING GLUCOSE TOLERANCE | |
TWI594758B (zh) | 包含雙歧桿菌的組合物、其製備方法及其用途 | |
ES2708450T3 (es) | Bacterias ácido lácticas y bifidobacterias para tratar endotoxemia | |
JP2009511469A (ja) | 脂肪代謝及び肥満に影響を及ぼすプロバイオティクス | |
KR20140000620A (ko) | 장신경계의 개선을 위한 프로바이오틱 균주의 용도 | |
KR20110081202A (ko) | 높은 옥살산 분해능을 갖는 유산균 | |
US20240115625A1 (en) | Roseburia hominis, eubacterium eligens, and combinations thereof as biotherapeutics | |
TW201705969A (zh) | 新穎馬利乳酸桿菌aps1及其用途 | |
KR101545551B1 (ko) | 인슐린 저항성 개선 효능을 갖는 7종의 유산균 복합균주를 유효성분으로 함유하는 조성물 | |
Jangra et al. | Milk fermented with Lactobacillus casei NCDC19 improves high fat and sucrose diet alters gene expression in obese mice | |
US11484557B2 (en) | Human-derived Lactobacillus fermentum MG4231 or Lactobacillus fermentum MG4244 strain having anti-obesity activity, and composition comprising same | |
KR101238836B1 (ko) | 혼합 유산균을 포함하는 비만 또는 비만 관련 질환 치료 또는 예방용 약제학적 조성물 또는 식품 조성물 | |
JP7181954B2 (ja) | 高いAhR活性化能を有する乳酸菌 | |
WO2018174125A1 (ja) | 脂質代謝改善用組成物 | |
US20200069748A1 (en) | Human-derived lactobacillus frementum mg4231 or lactobacillus frementum mg4244 strain having anti-obesity activity and composition comprising same | |
US20210268039A1 (en) | Use of leuconostoc mesenteroides subsp. mesenteroides sd23 for maternal fetal metabolic programming | |
TW202310862A (zh) | 發酵乳酸桿菌菌株與調節型t細胞用於組合療法以抑制體重增加以及預防或治療代謝疾病的用途 | |
JP5851242B2 (ja) | チオレドキシン誘導活性を有する乳酸菌ならびにチオレドキシンを介する生体傷害の予防および/または改善用の飲食品および医薬品 | |
CN117838737A (zh) | 一种短双歧杆菌207-1及其在调节脂代谢方向的应用 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
121 | Ep: the epo has been informed by wipo that ep was designated in this application |
Ref document number: 11823625 Country of ref document: EP Kind code of ref document: A1 |
|
ENP | Entry into the national phase |
Ref document number: 2810698 Country of ref document: CA |
|
ENP | Entry into the national phase |
Ref document number: 2012533018 Country of ref document: JP Kind code of ref document: A |
|
NENP | Non-entry into the national phase |
Ref country code: DE |
|
WWE | Wipo information: entry into national phase |
Ref document number: 2011823625 Country of ref document: EP |
|
WWE | Wipo information: entry into national phase |
Ref document number: 13821284 Country of ref document: US |